#### **Open Access Full Text Article**

#### REVIEW

## A systematic scoping review of adherence to reporting guidelines in health care literature

Zainab Samaan<sup>1-3</sup> Lawrence Mbuagbaw<sup>2</sup> Daisy Kosa<sup>2,4</sup> Victoria Borg Debono<sup>2,5</sup> Rejane Dillenburg<sup>6</sup> Shiyuan Zhang<sup>2</sup> Vincent Fruci<sup>7</sup> Brittany Dennis<sup>2</sup> Monica Bawor<sup>8</sup> Lehana Thabane<sup>2,5,9</sup>

Department of Psychiatry and Behavioral Neurosciences, McMaster University, Hamilton, <sup>2</sup>Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, <sup>3</sup>Population Genomics Program, McMaster University, Hamilton, <sup>4</sup>Department of Nephrology, Toronto General Hospital, Toronto, <sup>5</sup>Department of Anesthesia, McMaster University, Hamilton, <sup>6</sup>Department of Pediatrics, McMaster University, Hamilton, <sup>7</sup>Michael G DeGroote School of Medicine, McMaster University, Hamilton, <sup>8</sup>McMaster Integrative Neuroscience Discovery and Study (MiNDS) Program, McMaster University, Hamilton, 'Centre for Evaluation of Medicines, Hamilton, ON, Canada

Correspondence: Lehana Thabane Biostatistics Unit/FSORC, 50 Charlton Avenue East, St Joseph's Healthcare, Hamilton, 3rd Floor Martha Wing, Room H325, Hamilton, ON L8N 4A6, Canada Tel +1 905 522 1155 ext 33720/34905 Fax +1 905 528 7386 Email thabanl@mcmaster.ca **Background:** Reporting guidelines have been available for the past 17 years since the inception of the Consolidated Standards of Reporting Trials statement in 1996. These guidelines were developed to improve the quality of reporting of studies in medical literature. Despite the widespread availability of these guidelines, the quality of reporting of medical literature remained suboptimal. In this study, we assess the current adherence practice to reporting guidelines; determine key factors associated with better adherence to these guidelines; and provide recommendations to enhance adherence to reporting guidelines for future studies.

**Methods:** We undertook a systematic scoping review of systematic reviews of adherence to reporting guidelines across different clinical areas and study designs. We searched four electronic databases (Cumulative Index to Nursing and Allied Health Literature, Web of Science, Embase, and Medline) from January 1996 to September 2012. Studies were included if they addressed adherence to one of the following guidelines: Consolidated Standards of Reporting Trials (CONSORT), Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), Quality of Reporting of Meta-analysis (QUOROM), Transparent Reporting of Evaluations with Nonrandomized Designs (TREND), Meta-analysis Of Observational Studies in Epidemiology (MOOSE) and Strengthening the Reporting of Observational Studies in Epidemiology (STROBE). A protocol for this study was devised. A literature search, data extraction, and quality assessment were performed independently by two authors in duplicate. This study reporting follows the PRISMA guidelines.

**Results:** Our search retrieved 5159 titles, of which 50 were eligible. Overall, 86.0% of studies reported suboptimal levels of adherence to reporting guidelines. Factors associated with better adherence included journal impact factor and endorsement of guidelines, publication date, funding source, multisite studies, pharmacological interventions and larger studies.

**Conclusion:** Reporting guidelines in the clinical literature are important to improve the standards of reporting of clinical studies; however, adherence to these guidelines remains suboptimal. Action is therefore needed to enhance the adherence to these standards. Strategies to enhance adherence include journal editorial policies endorsing these guidelines.

Keywords: scoping, systematic, review, adherence, reporting, guidelines

#### Background

The medical literature is an integral component of clinical care, education, and research, as it has a serious impact on our understanding of health and disease. There are thousands of medical journals that publish articles related to clinical interventions, prognosis, diagnosis, and risks – among others – with an influence on health and life in general. For example, a quick glance at PubMed shows over 22 million citations for biomedical literature.<sup>1</sup> It is therefore a challenge to try to assimilate data presented in the literature and make evidence-based informed decisions. Attempts to summarize

© 2013 Samaan et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.

these data using systematic reviews are commendable as these reviews aim to provide a summary of the state of knowledge on a specific topic and address the inconsistent findings from single studies. However, these reviews are exponential in number and may report disparate findings. Searching for systematic reviews on depression resulted in 30,038 articles,<sup>2</sup> and in cancer resulted in 323,633.<sup>3</sup>

One way to assimilate and disseminate knowledge that can influence decision-making and provide an understanding of a certain condition is to perform a systematic review of reviews. The past few decades have given rise to a handful of such studies in several clinical areas including lifestyle interventions,<sup>4</sup> interventions to improve mental health,<sup>5</sup> homeopathy,<sup>6</sup> medical education,<sup>7</sup> spinal manipulation,<sup>8</sup> sleep medicine,9 and cancer,10 among others. Each of these reviews of reviews is focused on a specific clinical question. There is a paucity of systematic reviews that assess the quality of reporting of clinical studies across different clinical areas, and that use different reporting guidelines. The EQUATOR (Enhancing Quality and Transparency in Health Research) network is an international initiative that supports the development and dissemination of such guidelines.11 The EQUATOR website provides guidelines for the minimum information required to report research methods and findings for various kinds of medical research.12

The evidence that is presented in the clinical literature can carry substantial weight in informing professionals and users of health care on multiple aspects of health risks, disease, health care outcomes, and delivery. However, readers of the literature are faced with conflicting results presented in various formats and styles, making interpretations and conclusions challenging even for the most informed readers. For this reason, a consensus on reporting such evidence is needed to establish the quality of such studies. It is also important to ensure that a more uniform method is used by researchers to enable the combination of results from multiple studies and reach more standardized summaries and conclusions; this can minimize heterogeneity, which often complicates meta-analyses in future studies. Furthermore, poorly reported research can cause harm to patients and lead to the use of scarce resources on ineffective treatments.<sup>13</sup>

To address the concern over the quality of reported studies and ensure transparency in reporting clinical studies, the Consolidated Standards of Reporting Trials (CONSORT)<sup>14</sup> statement was produced as a collaborative effort to provide a checklist and flow diagram for authors to have as a guide to prepare reports on randomized controlled trials (RCTs) for publication. The CONSORT Statement was further updated in 2010 based on new evidence and an added focus on specific designs of RCTs.15 The CONSORT is a widely accepted and adopted statement that is well described in many freely accessible publications and websites. In brief, the CON-SORT Statement provides a 25-item checklist describing the required criteria for inclusion when reporting RCTs. Such items include the study design, the participants, interventions, outcomes, and sample size among others. It also recommends the inclusion of a flow diagram, accounting for recruitment, randomization, allocation of interventions, and retention in the study.16 Since the introduction of the CONSORT, several extensions and modifications of the original statement have been established to improve the quality of reporting of various study types, including observational studies, systematic reviews, and meta-analysis. Despite the availability of such guidelines for reporting, the quality of reporting of clinical studies has remained suboptimal with several manuscripts in a number of clinical areas missing key items as described in the CONSORT.16-23

Evidence suggests that the use of the CONSORT criteria is associated with improved standards of reporting.<sup>24,25</sup> However, it is not clear what the current level of adherence to reporting guidelines is, what factors are associated with improving the reporting of clinical literature, and how the results from different studies on reporting standards can be compiled to provide an overall conclusion on the current state of reporting standards.

We therefore undertook a systematic scoping review evaluating systematic reviews addressing the adherence standards to reporting guidelines published since the introduction of the CONSORT Statement in January 1996 to September 2012.

#### Study aims

In this study, we aimed to examine the extent of adherence to reporting guidelines in published clinical research since the introduction of the CONSORT Statement in 1996. The purpose of this systematic scoping review is to inform researchers, guideline developers, journal editors, and evidence users on the profile of reporting the existing literature and the current state of knowledge in the application of these guidelines. In particular, we will endeavor to address the following questions: (1) what is the current adherence to the reporting standards that include the CONSORT,<sup>26</sup> Strengthening the Reporting of Observational Studies in Epidemiology (STROBE),<sup>27</sup> Quality of Reporting of Meta-analysis – (QUOROM),<sup>28</sup> Transparent Reporting of Evaluations with Nonrandomized Designs (TREND),<sup>29</sup> (MOOSE),<sup>30</sup> and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines?<sup>31</sup> (2) What are the factors that are associated with adherence to reporting standards in medical literature? And (3) what guidance can we provide based on the current state of knowledge on adherence to reporting standards? More specifically the objectives of this review are to:

- 1. Report the levels of adherence to the above reporting guidelines in clinical research;
- 2. Determine the key factors associated with adherence to good reporting; and
- 3. Provide recommendations to enhance adherence to reporting guidelines for future studies.

We preselected the six guidelines above because they are among the oldest and the most popular, spanning through a wide range of study designs and clinical areas, and are therefore likely to be reported in systematic reviews, thus potentially generating a number of reviews to be included in this study.

#### Methods

We adopted a "systematic" scoping review approach – which is a combination of a scoping review methodology – to ensure the inclusion of broad areas of research and study designs, and a systematic review of reviews methodology.<sup>32,33</sup>

A scoping review is a relatively new type of study providing an assessment of available evidence from the literature in a broad area of research such as the compliance in the reporting of clinical studies to established guidelines. It also serves to identify gaps in the field and provide recommendations for implementation.32 The methodology of scoping reviews was first described in detail by Arksey and O'Malley<sup>32</sup> in their pivotal paper published in 2005, which provided a foundation for carrying out a scoping review. This framework was further operationalized, and five stages were proposed to be followed when conducting a scoping review, including: (1) the identification of a research question; (2) finding the relevant studies; (3) the selection of studies to be included in the review; (4) data extraction from the included studies; and (5) assembling, summarizing, and reporting the results of the review.34

The methods of conducting a systematic review of systematic reviews follow a similar approach, but include the provision of guidelines and suggestions for clinical practice, education, and research.<sup>33</sup> The aim of the methods and search strategy here is to ensure that the systematic review of reviews is comprehensive, thorough, and objective. We will report the results using the PRISMA (formerly QUOROM) reporting guidelines for systematic reviews.<sup>35</sup> A protocol was specifically designed for this study outlining the study design, search strategy, and selection criteria.

#### Data sources and search strategy

Electronic literature databases including Cumulative Index to Nursing and Allied Health Literature (CINAHL), Web of Science, Embase, and Medline (from January 1996 [date of CONSORT] to September 2012) were searched using a comprehensive search strategy designed with the assistance of a librarian who is experienced in conducting systematic reviews. The reference lists of identified articles were also reviewed for additional studies, and a manual search of key journals like BioMed Central systematic reviews, BioMed Central Research Methodology, and the Cochrane Library was conducted to avoid missing relevant reviews. Such search strategies are well supported for this type of systematic search and retrieval of relevant studies.<sup>36,37</sup> The databases were searched for the following key search terms: (Systematic reviews OR reviews OR quality of reporting OR completeness of reporting) AND (CONSORT OR STROBE OR QUOROM OR QUORUM OR PRISMA OR TREND OR MOOSE) OR adherence. For Web of Science, we also performed a forward citation search of the publications pertaining to reporting guidelines, whose acronyms might have other meanings, such as TREND and QUORUM. This helped us to decrease the occurrence of false positives in our search.

Initially, no language limits were set to identify the number of non-English reviews; however, a limit was then set for English language reviews only (which was necessary due to the lack of resources required to translate reviews from other languages). We also set the limits to "human" and "published complete systematic reviews."

#### Inclusion criteria

- Systematic reviews of clinical studies addressing the quality of reporting of the studies based on at least one of the six preselected reporting guidelines: CONSORT for RCTs; TREND for non-RCTs; STROBE for observational studies; and PRISMA (formerly QUOROM) or MOOSE for systematic reviews of RCTs or observational studies, respectively.
- 2. The systematic reviews must be complete (not abstracts only), reported in English, and investigating the quality of reporting in human studies of all age groups using one of the above guidelines.

**Dove**press

3. The quality of reporting guidelines must be the primary focus of the systematic review.

### **Exclusion** criteria

Systematic reviews were excluded if they were published as abstract only; the primary focus of the review was not on the quality of reporting; the quality of reporting was based on the standards of reporting that were different from the ones stated above, or if they were a duplicate publication of existing reviews (commentaries, letters, and editorials).

### Selection of systematic reviews

Two independent reviewers examined the titles and abstracts of all citations identified in the literature search. Articles were selected for full-text review if the inclusion criteria were met and if both reviewers considered the citation potentially relevant. Disagreement at any stage of study selection was resolved by discussion and consensus between the two reviewers. If agreement could not be reached, a third author was recruited to determine eligibility. Initial agreement between the two reviewers was calculated using the kappa statistic.<sup>38</sup>

Each reviewer independently:

- Assessed retrieved titles and abstracts for relevance and duplication;
- Screened full text articles deemed eligible for inclusion;
- Decided on including or excluding articles;
- Extracted relevant data using specifically designed data abstraction forms;
- Appraised the quality of the included reviews. A PRISMA flow diagram of included/excluded studies

is provided (Figure 1).35

## Quality assessment of systematic reviews

The quality of each systematic review that met the inclusion criteria for the study was assessed using a modified version of the assessment of multiple systematic reviews (AMSTAR, a validated tool to assess the methodological quality of systematic reviews).<sup>39-41</sup> Certain items of AMSTAR are not relevant to this type of review and cannot be assessed (eg, item 9, "Were the methods used to combine the findings of studies appropriate?"), as pooling of data may not be feasible in all systematic reviews of methodological quality, and should relate to the study question. In addition, item 10 ("Was the likelihood of publication bias assessed?") is irrelevant to this review, which is focused on the quality of reporting of published studies. Both of these items were omitted from the quality assessment.




Figure I Flow diagram for study selection.

Abbreviations: CINAHL, Cumulative Index to Nursing and Allied Health Literature; n, number.

We also used the modified version of the enhanced Overview Quality Assessment Questionnaire (OQAQ) to assess the quality of systematic reviews included in this study.<sup>42</sup> In addition to these tools, we assessed the quality of the reviews based on the following criteria: the use of explicit criteria to assess individual study quality using the guidelines checklist; explicit definition of the research question using a flow diagram to explain study selection; and a formal sample size calculation for the assessment of association.

## Data abstraction

A spreadsheet was created to record the following items from the selected reviews: authors, year of publication, number of primary studies included in the review, study location, study type, primary outcomes of the study, outcomes measures, and the overall results and conclusions. Two authors independently piloted the data extraction form for this review and modifications were made when necessary before reaching the final data abstraction forms used for this study. Data abstraction disagreements were resolved by discussion and consensus, and a third author extracted the data if an agreement could not be reached. Data collected from each systematic review included the study primary question, primary outcome, number of the studies included in the review, the statement investigated, quality assessment, the factors associated with adherence, the journal of publication, and whether the journal endorsed the statement in question.

### Analysis

The level of agreement between raters was estimated using the kappa statistic. The adherence to reporting standards was summarized, and key determinants of adherence were identified in a narrative manner.

## Results

#### Study selection

Our search retrieved 5159 articles from the four electronic databases searched. Following searching through the title, abstract, and full text screening, 50 articles were selected and included for data extraction and quality assessment (Figure 1). The strength of agreement between two independent raters on abstract screening was substantial (Kappa = 0.65; 95% confidence interval [CI] 0.53, 0.76; P < 0.001), and almost perfect for full text screening (Kappa = 0.94; 95% CI 0.85, 1.00; P < 0.001). Agreement was also substantial for the quality assessment using the modified OQAQ/AMSTAR checklist (Kappa = 0.63; 95% CI 0.42, 0.85; P < 0.001).

#### Study characteristics

Forty-one studies (82.0%) assessed RCTs using the CON-SORT Statement, five (10.0%) studies used the QUOROM checklist, and two studies (4.0%) used the PRISMA tool. The final three systematic reviews (6.0%) consisted of two reviews assessing both RCTs and observational studies using the CONSORT and STROBE guidelines, and the last study used both the QUOROM and PRISMA guidelines. The systematic reviews were published in a wide variety of journals and were led by authors from many different countries (Table 1). The median and interquartile range of the number of studies included in each review were 78 and 80.5, respectively.

#### Adherence to reporting guideline

The adherence of the studies included in the systematic reviews to their respective guidelines, and the author's conclusions, are shown in Table 2. Forty-three (86.0%) of the included studies concluded that the adherence to reporting guidelines was inadequate, poor, medium, or suboptimal, or that some improvement was needed. No combined, quantitative result was generated from the 50 systematic reviews due to differences in the measurement tools used by the individual reviews.

## **CONSORT** Statement

The adherence of RCTs to the CONSORT Statement was assessed with different versions of the CONSORT checklist. These checklists ranged from eight to 63 items, except for two studies that used the 212 subitem, Nelson–Moberg–Norton Expanded CONSORT instrument and the 201 subitem Nelson–Moberg Expanded CONSORT instrument. The revisions of the CONSORT Statements were usually based on the specific field of the RCT, and the applicability of the items on the CONSORT checklist to that field. For instance, Bian et al<sup>43</sup> used a revised 63-item CONSORT checklist designed for Chinese Herbal Medicine clinical trials. In addition to the CONSORT checklist, four studies (Augestad et al,<sup>44</sup> Balasubramanian et al,<sup>45</sup> Kiehna et al,<sup>46</sup> and Moher et al)<sup>47</sup> also used the five-point Jadad instrument to assess the quality of the individual RCTs.<sup>39</sup>

Of the 41 systematic reviews assessing RCTs reporting adherence to the CONSORT Statement, 33 (80%) of them concluded that some improvement was needed, or that the reporting quality was inadequate, poor, medium, or suboptimal (Table 3). Furthermore, the authors recommended the use of the CONSORT Statement as a guideline to improve the quality of reporting of RCTs. Eight studies did not report inadequate reporting quality of RCTs. Froud et al<sup>48</sup> concluded that cluster randomized trials in oral health had a reasonable quality. Fung et al<sup>49</sup> reported that the overall level of reporting was acceptable and the reporting quality has improved since the creation of CONSORT and STROBE statements. Ladd et al<sup>25</sup> also concluded that the overall reporting quality had improved since 1994 and the articles published in journals that endorse the CONSORT Statement had the highest levels of adherence to reporting guidelines. Moher et al<sup>47</sup> only compared the quality of pediatric complementary and alternative medicine RCTs and reported 40% of the CONSORT checklist items were included in these RCTs. Montgomery et al<sup>50</sup> evaluated the RCTs qualitatively and found that there was a varying level of reporting quality in factorial trials of complex interventions in community settings. Plint et al<sup>51</sup> compared RCTs from CONSORT-endorsing and nonendorsing journals, and their results suggested some improvement in the quality of reporting when the CONSORT checklist is used. Wangge et al<sup>52</sup> suggested that adherence to reporting guidelines for noninferiority trials have improved slightly since the CON-SORT Statement has been published. Lastly, Zintzaras et al53

#### Table I Characteristics of included studies

D	ov		n	r.	0	0	0
$\boldsymbol{\nu}$	U	C	Р	1	L	3	Э

First author	Year	Journal	City/country	Statement assessed	Number of studies
Al-Namankany <sup>54</sup>	2009	International Journal of Pediatric Dentistry	London, UK	CONSORT	173
Areia <sup>21</sup>	2009	Endoscopy	Coimbra, Portugal	CONSORT	120
Augestad <sup>44</sup>	2012	Journal of the American Medical informatics Association	Tromso, Norway	CONSORT	32
Balasubramanian <sup>45</sup>	2006	Annals of Surgery	Sheffield, UK	CONSORT	69
Bath <sup>55</sup>	1998	Stroke	London, UK	CONSORT	114
Bereza <sup>56</sup>	2008	Annals of Pharmacotherapy	Toronto, ON, Canada	QUOROM	16
Bian <sup>43</sup>	2006	Journal of Chinese Integrative Medicine	Hong Kong, People's Republic of China	CONSORT	66
Bousquet <sup>57</sup>	2010	Journal of Allergy and Clinical Immunology	Montpelier, France	CONSORT	94
Capili <sup>58</sup>	2010	Clinical Journal of Pain	New York, NY, USA	CONSORT	10
Cavadas <sup>59</sup>	2011	International Urogynecology Journal	Porto, Portugal	CONSORT	41
Chowers <sup>60</sup>	2009	Journal of Antimicrobial Chemotherapy	Kfar Saba, Israel	CONSORT	49
Cook <sup>61</sup>	2011	Medical Education	Minnesota, USA	STROBE	130
de Vries <sup>62</sup>	2010	Archives of Diseases in Childhood	Leeuwarden, Netherlands	CONSORT	107
Ethgen <sup>63</sup>	2009	BMC Medical Research Methodology	Paris, France	CONSORT	132
Eyawo <sup>64</sup>	2008	Trials	Burnaby, BC, Canada	CONSORT	47
Farrokhyar <sup>65</sup>	2007	Canadian Journal of Surgery	Hamilton, ON, Canada	CONSORT	50
Froud <sup>48</sup>	2012	Community Dentistry and Oral Epidemiology	London, UK	CONSORT	23
Fung <sup>49</sup>	2009	Ophthalmology	San Francisco, CA, USA	CONSORT,	36
				STROBE	
Gagnier <sup>66</sup>	2006	American Journal of Medicine	Toronto, ON, Canada	CONSORT	206
Halpern <sup>67</sup>	2008	International Journal of Obstetric Anesthesia	Toronto, ON, Canada	CONSORT	200 99
Hemels <sup>68</sup>	2004	Current Medical Research and Opinion	Paris, France	QUOROM	32
				•	32 37
Herdan <sup>69</sup> Junhua <sup>70</sup>	2011 2007	Gynecological Surgery The Journal of Alternative and Complementary Medicine	Bamberg, Germany Tianjin, People's Republic	CONSORT QUOROM	107
			of China		
Kiehna <sup>46</sup>	2011	Journal of Neurosurgery	Charlottesville, VA, USA	CONSORT	27
Kober <sup>71</sup>	2006	Journal of the National Cancer Institute	North Lyneham, Australia	CONSORT	142
Ladd <sup>25</sup>	2010	Addictive Behaviors	Albuquerque, NM, USA	CONSORT	127
Li <sup>72</sup>	2011	Evidence-Based Complementary and Alternative Medicine	Baltimore, MD, USA	CONSORT	42
Lu <sup>73</sup>	2011	Expert Review of Anticancer therapy	Guangzhou, People's Republic of China	CONSORT	46
Ma <sup>74</sup>	2011	PLoS One	Lanzhou, People's Republic of China	PRISMA	369
Marshman <sup>75</sup>	2010	Community Dental Health	Sheffield, UK	CONSORT	48
Moberg-Mogren <sup>76</sup>	2006	American Journal of Occupational Therapy	Cleveland, OH, USA	CONSORT	14
Moher <sup>47</sup>	2002	BMC Pediatrics	Ottawa, ON, Canada	CONSORT	251
Montané <sup>77</sup>	2010	BMC Clinical Pharmacology	Barcelona, Spain	CONSORT	92
Montgomery <sup>50</sup>	2010	Trials Journal	Bristol, UK	CONSORT	76
Norton-Mabus <sup>78</sup>	2008	OTJR: Occupation, Participation and Health	Toledo, OH, USA	CONSORT	30
Parsons <sup>79</sup>	2011	Journal of Bone and Joint Surgery. British Volume	Coventry, UK	CONSORT, STROBE	100
Piggott <sup>80</sup>	2004	Palliative Medicine	London, UK	CONSORT	93
Plint <sup>51</sup>	2004	Medical Journal of Australia	Ottawa, ON, Canada	CONSORT	8
Rios <sup>81</sup>	2008	Journal of Clinical Endocrinology and Metabolism	Hamilton, ON, Canada	CONSORT	89
Shea <sup>82</sup>	2008	The Journal of Rheumatology			89 57
		3 6/	Amsterdam, Netherlands		
Strech <sup>83</sup>	2011	Journal of Clinical Psychiatry	Hannover, Germany		105
Thabane <sup>84</sup>	2007	International Journal of Obesity	Hamilton, ON, Canada		63
Vigna-Taglianti <sup>85</sup>	2006	Annals of Oncology	Torino, Italy Banana Switzanland	QUOROM	80
Walleser <sup>86</sup>	2011	Journal of Clinical Epidemiology	Renens, Switzerland	CONSORT	106
Wangge <sup>52</sup>	2010	PLoS One	Utrecht, Netherlands		232
Weir <sup>87</sup>	2012	International Journal of Medical Informatics	Salt Lake City, UT, USA	PRISMA, QUOROM	13
Willis <sup>88</sup>	2011	BMC Medical Research Methodology	Manchester, UK	PRISMA	236
Zhong <sup>89</sup>	2011	European Journal of Integrated Medicine	Chengdu, People's Republic of China	CONSORT	153
Zintzaras <sup>53</sup>	2010	Clinical Therapeutics	Larisa, Greece	CONSORT	18
	2009	Annals of Epidemiology	Larisa, Greece	CONSORT	261

Abbreviations: CONSORT, Consolidated Standards of Reporting Trials; QUOROM, Quality of Reporting of Meta-analysis; BMC, BioMed central; STROBE, Strengthening the Reporting of Observational Studies in Epidemiology; PLoS, Public Library of Science; PRISMA, preferred reporting items for systematic reviews and meta-analyses; OTJR, Occupational Therapy Journal of Research.

CONSONT         Alrihum Jahyi         Nodiled 34 term CONSONT checklet         Consistence on term and arctie. Coord on planes or an another on terms.         Quarky of terms or terms and terms or terms of all alternation.         Quarky of terms or terms and terms or terms of alternation.         Quarky of terms or terms of alternation.           Areal         Areal         Application of CONSONT some action (8).         Non-reporting in another and terms or terms of terms or terms of alternation.         Level of alternation (4).         Level of alternation (4).           Areal         Application of CONSONT some action (8).         Level of alternation (4).         Level of alternation (4).           Areal         Application of CONSONT some alternation attract or terms or terms and terms of alternation (4).         Level of alternation (4).         Level of alternation (4).           Areal         Application of CONSONT some alternation attract or terms or terms or terms or terms or terms or terms o	Guideline	First author	Measure of quality	Results mean (SD)/% count	Authors' conclusion
Aread       Application of CONSORTSTAND       CONSORT for involution sections         Aread       Application of CONSORTSTAND       98%, Poor reporting in randomization         Aread       Application of CONSORTSTAND       98%, Poor reporting in randomization         Augestad*       CONSORT secore, allocation       98%, hour reporting in randomization         Augestad*       CONSORT secore, allocation       98%, hour reporting in randomization         Balaubramanin <sup>6</sup> CONSORT secore, allocation       98%, hour reporting in randomization         Modified CONSORT secore, allocation       98%, hour reporting in randomization         Balaubramanin <sup>6</sup> CONSORT secore, allocation       98%, hour reporting in randomization         Balaubramanin <sup>6</sup> CONSORT secore, allocation       98%, hour reporting unter ansistence         Balaubramanin <sup>6</sup> CONSORT secore, allocation       98%, hour reporting unter andomization         Balaubramanin <sup>6</sup> CONSORT secore, allocation       97, 40% of the trials had a jadd         Balaubramanin <sup>6</sup> Modified CONSORT secore, allocation       97, 20%         Balaubramanin <sup>6</sup> In all, 33 criteria of the CONSORT secore, allocation       97, 20%         Balaubramanin <sup>1</sup> In all, 33 criteria of the CONSORT secore       10, 40% of the trials had a jadd         Balaubramanin       In all, 33 criteria of the CONSORT secore	NSORT	Al-Namankanv <sup>54</sup>	Modified 34-item CONSORT checklist	Compliance varied across items and	Ouslity of reporting of BCTs in pediatric dental iournal
d*     CONSORT for inroduction sections sections (66%- 98%). Foor reporting in randomization methods (5%-98%), discussion sections (6%- 98%). Foor reporting in randomization methods (5%-98%), discussion sections (6%- 98%). Foor reporting in randomization methods (5%-98%), discussion sections (6%- 98%). Foor reporting in randomization methods (5%-9%), discussion sections (6%- 98%). Foor reporting in randomization methods (5%-9%), discussion sections (6%- 98%). Foor reporting in randomization methods (5%-9%), discussion sections (5%- 98%). Foor reporting in randomization methods (5%-9%), discussion sections (5%- 98%). Foor reporting in randomization methods (5%-9%), discussion sections (5%- 98%). Foor reporting and strend ad add store of 23 pains methods (5%-9%).       d*     CONSORT score, allocation corcellment as assessed by Schulz et al. jadd score diad score diad score diad score diad score diad score diad score diad score of 23 method score of 2					
af       CONSORT for inroduction sections (%:-9%), focustonis reactions (%%:- 9%). Poor reporting in randomization (%%), intention-to-treat amplisis (%)       CONSORT for introduction sections (%%:-9%), if section (%%), intention-to-treat amplisis (%)         d*       CONSORT adherence, jadad       30.75 (4), 40% of the trials had a jadad score (%), intention-to-treat amplisis (%)         d*       CONSORT adherence, jadad       30.75 (4), 40% of the trials had a jadad score eventionent amplisis (%)         modified CONSORT score, allocation correlation with a seven-point scale       30.75 (4), 40% of the trials had a jadad score (%)         nall 33 criteria of the CONSORT Statement or traits in greace.       30.75 (4), 40% of the trials had a jadad score (%)         nall 33 criteria of the CONSORT Statement or traits in greace.       30.75 (4), 40% of the trials had a jadad score (%)         nall 33 criteria of the CONSORT Statement or traits in greace to the Statement or traits in greace to the score of (%)       30.75 (4), 40% of the trials had a jadad score of (%)         nall 33 criteria of the CONSORT Statement of the state of (%)       30.75 (4), 40% of the trials had a jadad score of (%)         nall 33 criteria of the CONSORT Statement of the state of or traits states strict conduct of intervior-to-treat analysis.       30.75 (4), 40% of the trials had a jadad score of (%)         state of the point of the p				articles. Good compliance of articles to	was generally poor, with negligible improvement after the
d*       CONSORT of menodicion sections (5%-98%), discussion sections (5%-98%), foror reporting in randomization methods (7%-7%), discription of cample size calculation (4%), intention-to-treat analysis (1%)         d*       CONSORT adherence, jadad       28%), Poor reporting in randomization methods (7%-7%), discription actions (5%-7%), discription sections (5%-7%), discription of cample size calculation (4%), intention-to-treat analysis (1%)         amanian*       CONSORT adherence, jadad       3075 (4), 40% of the trials had a jadad score of =3 points         amanian*       Modified CONSORT score, allocation concellment, 377.7%       3075 (4), 40% of the trials had a jadad score of =3 points         and signal discore       31.3 criteria of the CONSORT statement and science of =3 points       3075 (4), 40% of the trials had a jadad score of =3 points         and signal discore       10.3 additional factors relevant to acute score of a paints       3075 (4), 40% of the trials respectively; 13% destrip vas 40% of the trial quality vas a slot score of a paints         and S3 additional factors relevant to acute score of a paints       31.3 addit score of a paints         with a seven-point scale       51.3 and interquaritie range guality vas 30% of KCIs had a jadad score of a paints         with a seven-point scale       51.3 addit score of oreall reporting quality vas 32% of KCIs had a jadad score of a support score of oreall reporting quality vas 32% of KCIs had a jadad score of a support score of oreall reporting quality vas 32% of KCIs had a jadad score of a support score of oreall reporting quality vas 32% of KCIs had a jadad score of a support sco					
d*       (%5-98%), discuston sectors (%5*- 98%), focor reporting in randomization methods (5*-%8), discuston sectors (%5*- 98%), focor reporting in randomization methods (5*-%8), discuston sectors (%5*- 98%), focor reporting in randomization methods (5*-%8), discuston sectors (%5*)         d*       CONSORT adhrence. Jadad       305 (4), 40% of the trials had a Jada size calculation (%5), intention-to-treat analysis (%)         d*       CONSORT adhrence. Jadad       305 (4), 40% of the trials had a Jada size calculation (%5), intention-to-treat analysis (%)         d*       CONSORT adhrence. Jadad       305 (4), 40% of the trials had a Jada size of a Jada         Jadad score       Modified CONSORT score, allocation correalment: 37.7% of 28-73.11 (b) tor RC15 from medical and surgical journals, respectively; 13% clearly vortials in general. Trial quality was allo surgical journals, respectively; 13% clearly vortials in general. Trial quality was allo surgical journals, respectively; 13% clearly vortials in general. Trial quality was allo surgical journals, respectively; 13% clearly vortials in general. Trial quality was allo surgical journals, respectively; 13% clearly vortials in general. Trial quality was allo surgical journals, respectively; 13% clearly vortials in general. Trial quality was allo surgical journals, respectively; 13% clearly vortials in general. Trial quality was allo surgical journals; respectively; 13% clearly vortials in general.         strict conduct of internotorest strict conduct of internotorest strict conduct of internotorest and strict conduct of internotorest and strict conduct of internotorest and strict conduct of internotor vortical strict conduct of internotor vortical strict conduct of internotow vortical strict conduct of internotor vortical strict				CONSORT for introduction sections	publication of COINSOR I statement
************************************				(96%–98%), discussion sections (96%–	
d*     CONSORT adherence, Jadd     20.75 (4), 46% of the trials had a Jadd acoustion of CONSORT adherence, Jadd       d*     CONSORT adherence, Jadd     30.75 (4), 40% of the trials had a Jadd acoustion of CONSORT acoustion       ammian*     Modified CONSORT score, allocation     30.75 (4), 40% of the trials had a Jadd acoustion of CONSORT acoustion       ammian*     Modified CONSORT score, allocation     30.75 (4), 40% of the trials had a Jadd acoustion       ammian*     Modified CONSORT score, allocation     30.75 (4), 40% of the trials had a Jadd acoustion       ammian*     Modified CONSORT score, allocation     30.75 (4), 40% of the trials had a Jadd acoustion       ammian*     Modified CONSORT score, allocation     30.75 (4), 40% of the trials had a Jadd acoustion       Jadd score     Jadd score     30.75 (4), 70.20       In all, J3 criteria of the CONSORT statement     and state score       and S3 additional factors relevant to acute stroke     angrad Journals, respectively; 13% dearly acoustion       ort trials is general. Trial quality was abo assessed by stroke acousting undifier     5.61). Median CONSORT       ort trials is general. Trial quality was abo assessed by stroke acousting undifier     5.61). Median CONSORT       ort trials is general. Trial quality was abo assessed by stroke acousting updifier     5.61). Median CONSORT       of the consort trial stroke     and stroke acousting updifier     5.61). Median CONSORT strement       offer enderline clinical strudies				98%). Poor reporting in randomization	
d*     CONSORT adherence. Jada     30.75 (4), 40% of the traits had a Jada score       d*     CONSORT adherence. Jada     30.75 (4), 40% of the traits had a Jada score of ≥3 points       amanian*     Modified CONSORT score, allocation     30.75 (4), 40% of the traits had a Jada score of ≥3 points       amanian*     Modified CONSORT score, allocation     30.75 (4), 40% of the traits had a Jada score of ≥3 points       amanian*     Modified CONSORT score, allocation     30.75 (4), 40% of the traits had a Jada score of ≥3 points       amanian*     Modified CONSORT score, allocation     30.75 (4), 40% of the traits had a Jada score of ≥3 points       amonian*     In all. 33 criteria of the CONSORT Statement of a diamonal fractors relevant to acute score of ≥3 points     30.9-461.31 (1) for RCTs from medical and virgit a seven-point scale       and 53 additional fractors relevant to acute score of scale     Median total reporting quality was also assessed with a seven-point scale     Median total reporting quality was 40% (in and in the index) of the studies       afree Herbal Medicine clinical studies     Median total reporting quality was also assessed with eight items of the conSORT fractment.     37.35 (9-29)       etail     Beporting of procedure, randomization, dropouts     Median total reporting quality was assessed with eight items of the CONSORT fractment.       etail     Beporting of procedure, randomization, dropouts     S7.85 (8%)       etail     S7.85 (8%)     Median total reporting quality was 22% (8%)       etail<					
d*       CONSORT adherence. Jatad       30.75 (4), 40% of the trials had a jadad sorie         d*       CONSORT adherence. Jatad       30.75 (4), 40% of the trials had a jadad sorie         amanian*       Molfield CONSORT score, allocation       30.75 (4), 40% of the trials had a jadad sorie         amanian*       Molfield CONSORT score, allocation       30.75 (4), 40% of the trials had a jadad sorie         amanian*       Molfield CONSORT score, allocation       30.75 (4), 40% of the trials had a jadad sorie of a 3 points         amanian*       Molfield CONSORT score, allocation       30.75 (4), 40% of the trials had a jadad sorie of a 3 points         in all, 33 criteria of the CONSORT Statement and slocation concellment; 37.7% of RCTs had a jadad sorie of a 3 jadditional factors relevant to acute stroke of rise in general. Trial quality was also assessed with a seven-point scale       30.75 (4), Molan CONSORT scale         or trials in general. Trial quality was also assessed with a seven-point scale       5.40.1. Modian CONSORT scale         or trials in general. Trial quality was also assessed with eight terms strice conducts of intention-to-treat analysis.       Median score of overall reporting quality was 32% (8%)         ***       Reporting of procedure, randomization, dropouts       Median score of overall reporting quality was 32% (8%)         ***       Reporting of procedure, randomization, dropouts       ************************************					
dr     CONSORT adhrence. Jadd     30.75 (4), 40% of the trials had a Jadd       amarian <sup>6</sup> CONSORT adhrence. Jadd     30.75 (4), 40% of the trials had a Jadd       amarian <sup>6</sup> CONSORT score. allocation     30.75 (4), 40% of the trials had a Jadd       amarian <sup>6</sup> Modified CONSORT score. allocation     30.75 (4), 40% of the trials had a Jadd       amanian <sup>6</sup> Modified CONSORT score. allocation     30.75 (4), 40% of the trials had a Jadd       amanian <sup>6</sup> Modified CONSORT score. allocation     30.75 (4), 40% of the trials had a Jadd       Jadd score     (5.28)-73.11) for RCTs from medical and suggral journals. respectively.13% dearty explained allocation corealment. 37.7% of RCTs had a Jadd score of 23 a Jaditional factors relevant to acute stroke of range 15-(1). Median scole revised and suggral journals. respectively.13% dearty explained allocation corealment. 37.7% of RCTs had a Jadd score of 23 Jaditional factors relevant to acute stroke of verall reporting quality was also assessed with a seven-point scale       and 53 additional factors relevant to acute stroke of verall reporting quality was also assessed with a seven-point scale     Median scale reporting quality was 40% (and score of 29)       with a seven-point scale     33.7% of the studies met the eight items stroke of overall reporting quality was 23% (%)       etc.     Asporting of procedure, randomization, dropouts       stroit conduct of intention-to-treat analysis, segred with ected and score of overall reporting quality was 23% (%)       etc.     Asporting of procedure, randomization, dropouts       stro				size calculation (4%), intention-to-treat	
d*     CONSORT statement     157, (2.)       d*     CONSORT adherence, jadad     30.75 (4), 40% of the trials had a jadad       armanian*     Modified CONSORT score, allocation     30.75 (4), 40% of the trials had a jadad       armanian*     Modified CONSORT score, allocation     30.75 (4), 40% of the trials had a jadad       armanian*     Modified CONSORT score, allocation     30.75 (4), 40% of the trials had a jadad       armanian*     Modified CONSORT score, allocation     30.75 (4), 40% of the trials had a jadad       jadad score     S.0     S.0.13) and interquartile range 68.97 (5.0.98-73.11) for RCTs from medical and surgical journals, respectively; 13% clearly of RCTs had a jadad score of 23       In all, 33 criteria of the CONSORT checklist designed for trials in general. Trial quality was also assessed with a seven-point scale     Median score of overall reporting quality was 40% (range 15-61). Median CONSORT       S3-item revised CONSORT checklist designed for was 1973 (9-29)     Median score of overall reporting quality was 32% (8%)       etails in general. Trial quality was also assessed with a seven-point scale     Median score of overall reporting quality was 32% (8%)       etails in general. Trial quality was also assessed with a seven-point scale     Median score of overall reporting quality was 32% (8%)       etails in general. Trial quality was also assessed with effectine cinical studies     Median score of overall reporting quality was 32% (8%)       etails in general. Trial quality was also assessed with effectine cinical studies     Medi				analysis (1%)	
d <sup>4</sup> CONSORT adherence, jadad         amanian <sup>4</sup> Modified CONSORT score, allocation         and score       diara soft the modified and score         jadad score       0(1)         and score       0(2, 28)-73.11)         in al. 33 criteria of the CONSORT Statement at 33 additional factors relevant to acute score or rotals in general rrial quality was also assessed with a seven-point scale       0(2, 28)-73.11)         in al. 33 criteria of the CONSORT checklist designed for with a seven-point scale       0(2, 28)-73.11)         in al. 33 criteria of the CONSORT checklist designed for with a seven-point scale       0(2, 28)-73.11)         or trais in general rrial quality was also assessed with a scale scale for with a seven-point scale       0(2, 28)-73.11)         of trais in general rrial quality was also assessed with a score of overall report quality was 40%6       (range 15-61). Median col Score of 2-30         diana score of overall report quality was 40%6       (range 15-61). Median col Score of 2-30         diana score of overall report quality was 40%6       (range 15-61). Median col Score of 2-30         diana score of overall report quality was 40%6       (range 15-61). Median col Score of 2-30         din trent as addition with w		Areia <sup>21</sup>	Application of CONSORT/STARD	15.7 (2.2)	Level of adherence is medium for quality of reporting in
d*       CONSORT adherence, Jada       30.75 (4), 40% of the traits had a Jada         amanian*       Modified CONSORT score, allocation       30.75 (4), 40% of the traits had a Jada         amanian*       Modified CONSORT score, allocation       30.75 (4), 40% of the traits had a Jada         amanian*       Modified CONSORT score, allocation       30.75 (4), 40% of the traits had a Jada         Jadd score       Jadd score       81.99–66.13) and interquaritie range 68.97         Jadd score       81.99–66.13) and interquaritie range 68.97       928–73.11) for RCTs from medical and score of a Jadad					diagnostic endoscopy
<ul> <li>amanian<sup>6</sup> Modified CONSORT score, allocation</li> <li>amanian<sup>6</sup> Modified CONSORT score allocation</li> <li>correalment as assessed by Schulz et al, Jada score</li> <li>median sof the modified CONSORT</li> <li>median sof secore were 85.45 (interquartile range 68.97 (32.89–731.11) for RCTs had a Jadad score of ≥3</li> <li>mall 33 additional factors relevant to acute stroke or trials in general. Trial quality was also assessed with a seven-point scale</li> <li>G3 additional factors relevant to acute stroke or trials in general. Trial quality was also assessed with a seven-point scale</li> <li>G3 additional factors relevant to acute stroke or trials in general. Trial quality was also assessed with a seven-point scale</li> <li>G3 addition dalocation concealment, 37.7% of RCTs had a Jadad score of ≥3</li> <li>median total reporting quality was 32% (8%)</li> <li>median score of overall reporting quality was 32% (8%)</li> <li>mention-to-treat analysis, sample size calcution, which was assessed with energine interns of the CONSORT Statement didense in RCTs</li> <li>Pour of the 94 studies met the eight items guidelines in RCTs</li> <li>Pour of the 94 studies met to reiteria guidelines in RCTs</li> <li>Pour of the 94 studies met to reiteria guidelines in RCTs</li> <li>Pour of the CONSORT Statement</li> <li>Pour of the studies met reiteria guidelines in RCTs</li> <li>Pour of the Studies met to reiteria guidelines in RCTs</li> <li>Pour of the Studies met to reiteria guidelines in RCTs</li> <li>Pour of the studies met to reiteria guidelines in RCTs</li> <li>Pour of the studies met to reiteria guidelines in RCTs</li> <li>Pour of the studies met to reiteria guidel</li></ul>		Augestad <sup>44</sup>	CONSORT adherence. ladad	30.75 (4). 40% of the trials had a ladad	Level of adherence is low for guality of reporting for
<ul> <li>manian<sup>6</sup> Modified CONSORT score, allocation concellment as assessed by Schulz et al, Jadad score core assessed by Schulz et al, Jadad score core seres 85.45 (interquartile range 86.97 (32.89–31.11) for RCT5 from medical and surgical journals, respectively; 13% clearly explained allocation concellment; 37.7% of R2.9–31.11) for RCT5 from medical and surgical journals, respectively; 13% clearly explained allocation concellment; 37.7% of RCT5 had a Jadad score of a 3 additional factors relevant to acute stroke or trials in general. Trial quality was also assessed with a seven-point scale</li> <li>Reporting of procedure, randomization, dropouts, sample size calculation, which was assessed with eight items of the CONSORT Statement.</li> <li>Reporting of procedure, randomization, dropouts, sample size calculation, which was assessed with eight items of the CONSORT Statement.</li> <li>Reporting of procedure, randomization, dropouts, surgice 16–61, Median CONSORT statement.</li> <li>Reporting of procedure, randomization, dropouts, as 32% (8%)</li> <li>Reporting of procedure, randomization, dropouts, as 22% (8%)</li> <li>Reporting of procedure, randomization, dropouts, as 32% (8%)</li> <li>Reporting of procedure, randomization, dropouts, as 22% (8%)</li> <li>Reporting of procedure, randomization, dropouts, as 32% (8%)</li></ul>		0		score of $>3$ points	RCTs of disease specific clinical decision support
effection       Productor       Four of the CONSORT statement         pladd score       Bio -86.15 (interquartile range 66.97 (32.89–73.11) for RCTs from medical and surgical journals, respectively, 13% clearly explained allocation concealment; 37.7% of RCTs had a jada score of ≥ 3         In all, 33 criteria of the CONSORT Statement and 53 additional factors relevant to acute stroke or trials in general. Trial quality was also assessed with a seven-point scale       Bio -86.15 (interquartile range 66.97 (32.89–73.11) for RCTs from medical and surgical journals, respectively, 13% clearly explained allocation concealment; 37.7% of RCTs had a jada score of ≥ 3         in all, 33 criteria of the CONSORT statement to acute stroke or trials in general. Trial quality was also assessed with a seven-point scale       Median total reporting quality was 40/86 (range 15-61). Median CONSORT checklist designed for were 87.5% (8%)         et <sup>67</sup> Reporting of procedure, randomization, dropouts, strict conduct of intention-to-treat analysis, sample size calculation, which was assessed with eight items of the CONSORT Statement criteria strict conduct of intention-to-treat analysis, as 32% (8%)       Four of the 94 studies met the eight items of the CONSORT Statement criteria strict conduct of intention-to-treat analysis, as 32% (8%)         strict conduct of intention-to-treat analysis, subjectively intens were reported in more than eight items were reported in more than a stroke consorted in more than a stroke consorted in the studies; stroke studies; stroke strokes; strokestrokes; strokes; stroke strokes; strokes; stroke stroke		Delecthromosica 45			Continue of manage specific curricul accision support
at       33 additional factore       309-46.13) and interquarile range 68.97         jadad score       6.289-73.11) for RCTs from medical and surgical journals, respectively, 13% clearly explained allocation concealment; 37.7% of any statement and surgical journals, respectively, 13% clearly explained allocation concealment; 37.7% of any statement; and surgical journals, respectively, 13% clearly explained allocation concealment; 37.7% of any statement; and surgical journals, respectively, 13% clearly explained allocation concealment; 37.7% of any statement; and surgical journals, respectively, 13% clearly explained allocation concealment; 37.7% of any statement; and surgical journals, respectively, 13% clearly explained allocation concealment; 37.7% of any statement; and surgical journals, respectively, 13% clearly explained allocation concealment; 37.7% of the surgical journals, respectively, 13% clearly explained allocation concealment; 37.7% of the surgical journals, statement; and unside and surgical journals, statement; and surgical journals, was 32% (8%)         etail       Reporting of procedure, randomization, dropouts; and surgical			riduilled CONSONT score; allocation		Cuality of reporting of surgical NCTS was supplyingly a report of the resonant of the report of the
andar score       and score of an interquarture range oo.27         padar score       (6.297-31.1) for RCTs from medical and surgical journals, respectively, 13% clarity versible of the CONSORT Statement and surgical journals, respectively, 13% clarity versible of the CONSORT Statement and S3 additional factors relevant to acute stroke or rarials in general. Trial quality was also assessed with a seven-point scale       (6.297-31.1) for RCTs from medical and surgical journals, respectively, 13% clarity versible of the CONSORT Statement and S3 additional factors relevant to acute stroke or rarials in general. Trial quality was also assessed with a seven-point scale       (6.297-31.1) for RCTs form medical and surgical journals, respectively, 13% clarity versible or rarials in the seven-point scale         e11, 33 criteria of the CONSORT checklist designed for versal reporting quality was also assessed with eight tiens scale       Median total reporting quality was 40.86         e12, item revised CONSORT checklist designed for versal reporting quality was assessed with eight tiens scale       Median score of overal reporting quality was 32% (8%)         e13       Reporting of procedure, randomization, dropouts, strict conduct of intention-to-treat analysis, sample size calculation, which was assessed with eight tiens of the CONSORT/presence of harms, strict conduct of intention-to-treat analysis, sample size calculation, which was assessed with eight tiens of the CONSORT/presence of harms, stroked CONSORT fattement         ***       Adherene to CONSORT fattement       7/3% for harm         ***       Adherene to CONSORT fattement       7/3% for harm         ***       Adherene to CONSORT fattement <td></td> <td></td> <td></td> <td></td> <td></td>					
************************************			Jadad score	81.07–86.13) and interquartile range 66.77	
************************************				(62.89–73.11) for RCTs from medical and	"We found that the quality of reporting of general
<ul> <li><sup>10</sup> In al., 33 criteria of the CONSORT Statement and 53 additional factors relevant to acute stroke of a Jada score of a Jada sc</li></ul>				surgical journals, respectively; 13% clearly	surgical RCTs leaves considerable room for
1n all, 33 criteria of the CONSORT Statement and 53 additional factors relevant to acute stroke or trials in general. Trial quality was also assessed with a seven-point scale       of RCTs had a Jadad score of ≥3 Median total report quality was 40/86 (range 15-61). Median CONSORT criterion was 19/33 (9-29)         etain total report quality was also assessed with a seven-point scale       Gi RCTs had a Jadad score of ≥3 Median total report quality was 40/86 (range 15-61). Median CONSORT criterion was 19/33 (9-29)         etain total studies       Gi report up ality was 40/86 (range 15-61). Median CONSORT criterion was 19/33 (9-29)         etain total studies       Median total reporting quality was 32% (8%)         etain score of overall reporting quality was 32% (8%)         etain score of overall reporting quality was 32% (8%)         etain score of overall reporting quality was 32% (8%)         etain score of narms gight items of the CONSORT Statement Adherence to CONSORT Statement didelines in RCTs         etain 2010 revised CONSORT Statement 27.3% for harm         etain 2010 revised CONSORT Statement Adherence to CONSORT Statement Adherence to CONSORT Statement Proceed in less ten 30% of the studies streported in less ten 30% of the studies				explained allocation concealment; 37.7%	improvement"
1all. 33 criteria of the CONSORT Statement and 53 additional factors relevant to acute stroke or trials in general. Trial quality was also assessed with a seven-point scale       Median total report quality was 40/86 (range 15-61). Median CONSORT criterion was 19/33 (9-29)         or trials in general. Trial quality was also assessed with a seven-point scale       Median total reporting quality was 32% (8%)         etain total reporting quality with a seven-point scale       Median total reporting quality was 32% (8%)         etain total reporting of procedure, randomization, dropouts strict conduct of intention-to-treat analysis, sample size calculation, which was assessed with eight items of the CONSORT Statement Adherence to CONSORT Statement       Four of the 94 studies met the eight items of the CONSORT Statement of the CONSORT Statement         . <sup>93</sup> 25-item 2010 revised CONSORT Statement addialines in RCTs       Torage: 14–21) for CONSORT; 7/22 = 773% cf har				of RCTs had a Jadad score of $\ge 3$	
and 53 additional factors relevant to acute stroke or trials in general. Trial quality was also assessed with a seven-point scale       (ange 15–61). Median CONSORT criterion was 19/33 (9–29)         or trials in general. Trial quality was also assessed with a seven-point scale       (ange 15–61). Median CONSORT criterion was 19/33 (9–29)         63-item revised CONSORT checklist designed for Chinese Herbal Medicine clinical studies       (ange 15–61). Median CONSORT criterion was 19/33 (9–29)         Reform revised CONSORT checklist designed for Chinese Herbal Medicine clinical studies       (ange 15–61). Median CONSORT criterion was 19/33 (9–29)         Reform revised CONSORT checklist designed for Chinese Herbal Medicine clinical studies       (ange 15–61). Median CONSORT criterion was 19/33 (9–29)         Reform revised CONSORT checklist designed for strict conduct of intention-to-treat analysis, sample size calculation, which was assessed with eight items of the CONSORT Statement Adherence to CONSORT Statement didelines in RCTs       Four of the 94 studies met the eight items of the CONSORT Statement criteria         9-3       25-item 2010 revised CONSORT Statement criteria       17 (range: 14–21) for CONSORT; 7/22 = 77.3% for harm         9-3       25-item 2010 revised CONSORT Statement criteria       No combined data: only a few items were reported in more than 500° of the studies;		Bath <sup>55</sup>	In all, 33 criteria of the CONSORT Statement	Median total report quality was 40/86	Poor quality for acute stroke RCTs
effection       seven-point scale       criterion was 19/33 (9-29)         or trials in general. Trial quality was also assessed with a seven-point scale       median score of overall reporting quality was 32% (8%)         effection       seven-point scale       median score of overall reporting quality was 32% (8%)         effection       seven-point scale       median score of overall reporting quality was 32% (8%)         effection       seven-point scale       median score of overall reporting quality was 32% (8%)         effection       seven-point scale       median score of overall reporting quality was 32% (8%)         effection       seven-point scale       median score of overall reporting quality was 32% (8%)         effection       seven scale       median score of overall reporting quality was 32% (8%)         effection       seven scale       seven scale         effection       seven scale       seven scale         eight items of the CONSORT Statement guidelines in RCTs       four of the 94 studies met the sight items of the CONSORT Statement         effection       seven scale       77.3% for harm         effection       seven scale       77.3% for harm         effection       seven scale       77.3% for harm         effection       seven scale       reported in more than			and 53 additional factors relevant to acute stroke	(range 15–61). Median CONSORT	"We helieve that authors should follow the CONSOR"
<ul> <li><sup>150</sup> Seven-point scale</li> <li><sup>151</sup> G3-item revised CONSORT checklist designed for chinese Herbal Medicine clinical studies</li> <li><sup>152</sup> Sitem revised CONSORT checklist designed for was 32% (8%).</li> <li><sup>153</sup> Reporting of procedure, randomization, dropours, strict conduct of intention-to-treat analysis, sample size calculation, which was assessed with eight items of the CONSORT Statement analysis, and eight items of the CONSORT Statement and arrai on the formation and the revised of the CONSORT Statement and therence to CONSORT Statement and arrai on the formation and the studies in RCTs</li> <li><sup>159</sup> A 25-item 2010 revised CONSORT Statement and the revised array of the the rank of the studies in RCTs</li> <li><sup>150</sup> A 25-item 2010 revised CONSORT Statement and the revised array of the the rank of the studies are the sight items of the consort of the studies are the regist items of the consort statement array of the studies are the statement array of the studies are the studie</li></ul>			or trials in general Trial multity was also assessed	criterion was 19/33 (9–29)	anidelines and that referees and editors should ensure
<sup>51</sup> Sitem revised CONSORT checklist designed for Ginese Herbal Medicine clinical studies chinese Herbal Medicine clinical studies reporting of procedure, randomization, dropouts, strict conduct of intention-to-treat analysis, sample size calculation, which was assessed with eight items of the CONSORT Statement criteria supple size calculation, which was assessed with eight items of the CONSORT Statement criteria 373% for harm of the CONSORT, 7/22 = 773% for harm of the studies than 50% of the studies reported in less than 50% of the studies reported in less than 50% of the studies of the studies			with a seven-point scale		this hannens."
est       Chinese Herbal Medicine clinical studies       vas 32% (8%)         est       Reporting of procedure, randomization, dropouts, strict conduct of intention-to-treat analysis, sample size calculation, which was assessed with eight items of the CONSORT Statement and therence to CONSORT Statement and the construct of the Statement and the construct of the CONSORT Statement and the construct of the CONSORT Statement and the construct of the Statement and the construct of the CONSORT Statement and the construct of the Statement and the construct of the CONSORT Statement and the construct of the Statement and the construct of the Statement and the construct of the studies; some items were reported in more than 90% of the studies;		<b>1</b>		M - H	
chinese Herbal Medicine clinical studies       was 32% (8%)         Reporting of procedure, randomization, dropouts, strict conduct of intention-to-treat analysis, sample size calculation, which was assessed with eight items of the CONSORT Statement criteria sumple size calculation, which was assessed with eight items of the CONSORT Statement criteria         9       325-item 2010 revised CONSORT Statement         77.3% for harm       No combined data: only a few items were reported in more than 90% of the studies;		Blan	63-item revised COINSORT checklist designed for	Median score of overall reporting quality	Overall quality of reporting of CHM RC Is was poor.
<sup>15</sup> Reporting of procedure, randomization, dropouts, strict conduct of intention-to-treat analysis, sample size calculation, which was assessed with eight items of the CONSORT Statement criteria sample size calculation, which was assessed with eight items of the CONSORT Statement criteria of the CONSORT Statement criteria sample size calculation, which was assessed with eight items of the CONSORT Statement criteria of the CONSORT Statement criteria sample size calculation, which was assessed with eight items of the CONSORT Statement criteria of the CONSORT Statement criteria analysis, analysis, so the CONSORT Statement criteria sample size calculation, which was assessed with eight items of the CONSORT Statement criteria analysis, a			Chinese Herbal Medicine clinical studies	was 32% (8%)	Need to improve reporting in clinical trials in this area.
<ul> <li>Reporting of procedure, randomization, dropouts, strict conduct of intention-to-treat analysis, sample size calculation, which was assessed with eight items of the CONSORT Statement criteria sample size calculation, which was assessed with eight items of the CONSORT Statement criteria of the CONSORT Statement criteria</li> <li>Partice conduct of intention-to-treat analysis, so the CONSORT Statement criteria</li> <li>Partice conduct of intention-to-treat analysis, so the CONSORT Statement criteria</li> <li>Partice conduct of intention-to-treat analysis, so the culois in RCT</li> <li>Partice conduct of intention-to-treat analysis, so the studies; so t</li></ul>					"To improve the quality of reporting of RCTs of CHM,
<ul> <li>Reporting of procedure, randomization, dropouts, strict conduct of intention-to-treat analysis, sample size calculation, which was assessed with eight items of the CONSORT Statement criteria sample size calculation, which was assessed with eight items of the CONSORT Statement criteria of the CONSORT Statement criteria</li> <li>Partice conduct of intention-to-treat analysis, so the CONSORT Statement criteria</li> <li>Partice conduct of intention-to-treat analysis, so the CONSORT Statement criteria</li> <li>Partice conduct of intention-to-treat analysis, so the CONSORT Statement criteria</li> <li>Partice conduct of intention-to-treat analysis, so the studies; so the studies; so the studies;</li> </ul>					we recommend adopting a revised CONSORT checkli
<ul> <li>Reporting of procedure, randomization, dropouts, strict conduct of intention-to-treat analysis, sample size calculation, which was assessed with eight items of the CONSORT Statement criteria sample size calculation, which was assessed with eight items of the CONSORT Statement criteria sample size calculation, which was assessed with eight items of the CONSORT Statement criteria of the CONSORT Statement criteria</li> <li><sup>59</sup> A 25-item 2010 revised CONSORT Statement analysis, some items were reported in less than 50% of the studies; some items were reported in more than 90% of the studies;</li> </ul>					that includes items specific to CHM. We also recomme
<ul> <li>Reporting of procedure, randomization, dropouts, strict conduct of intentionto-treat analysis, sample size calculation, which was assessed with eight items of the CONSORT Statement criteria sample size calculation, which was assessed with eight items of the CONSORT Statement criteria sample size calculation, which was assessed with eight items of the CONSORT Statement criteria of the CONSORT Statement criteria sample size calculation, which was assessed with eight items of the CONSORT Statement criteria sample size calculation, which was assessed with eight items of the CONSORT Statement criteria sample size calculation, which was assessed with eight items of the CONSORT Statement criteria sample size calculation, which was assessed with eight items of the CONSORT Statement criteria sample size calculation, which was assessed with eight items of the CONSORT Statement criteria assessed with eight items of the studies; some items were reported in more than 90% of the studies;</li> </ul>					that editors of CHM journals require authors to use
<ul> <li>Reporting of procedure, randomization, dropouts, strict conduct of intentionto-treat analysis, sample size calculation, which was assessed with eight items of the CONSORT Statement criteria sample size calculation, which was assessed with eight items of the CONSORT Statement criteria assessed with eight items of the CONSORT Statement criteria assessed with eight items of the CONSORT Statement criteria assessed with eight items of the CONSORT Statement criteria assessed with eight items of the CONSORT Statement criteria assessed with eight items of the CONSORT Statement criteria assessed with eight items of the Studies; some items were reported in more than 00% of the studies;</li> </ul>					a structured approach to proceeding their triple as a
<ul> <li>Reporting of procedure, randomization, dropouts, trait</li> <li>Reporting of procedure, randomization, dropouts, trait</li> <li>Reporting of procedure, randomization, dropouts, strict conduct of intention-to-treat analysis, of the CONSORT Statement criteria sample size calculation, which was assessed with eight items of the CONSORT Statement criteria</li> <li>Reported in less than 50% of the studies; some items were traited in more than 90%. of the studies;</li> </ul>					
21 <sup>57</sup> Reporting of procedure, randomization, dropouts, strict conduct of intention-to-treat analysis, strict conduct of intention-to-treat analysis, of the CONSORT Statement criteria sample size calculation, which was assessed with eight items of the CONSORT Statement criteria sample size calculation, which was assessed with eight items of the CONSORT Statement criteria gind titems of the CONSORT Statement criteria         29       A 25-item 2010 revised CONSORT Statement         29       A 25-item 2010 revised CONSORT Statement         29       A 25-item 2010 revised CONSORT Statement         2000, of the studies;       some items were reported in more than 90% of the studies;					condition of publication"
strict conduct of intention-to-treat analysis,       of the CONSORT Statement criteria         sample size calculation, which was assessed with       eight items of the CONSORT Statement         asimple size calculation, which was assessed with       17 (range: 14–21) for CONSORT; 7/22 =         Adherence to CONSORT/presence of harms       77.3% for harm         guidelines in RCTs       No combined data: only a few items were         A 25-item 2010 revised CONSORT Statement       No combined data: only a few items were         some items were reported in more than       90% of the studies;		Bousquet <sup>57</sup>	Reporting of procedure, randomization, dropouts,	Four of the 94 studies met the eight items	RCTs in subcutaneous immunotherapy and sublingual
sample size calculation, which was assessed with eight items of the CONSORT Statement Adherence to CONSORT/presence of harms guidelines in RCTs A 25-item 2010 revised CONSORT Statement Preported in less than 50% of the studies; some items were reported in more than P0%, of the studies;			strict conduct of intention-to-treat analysis,	of the CONSORT Statement criteria	immunotherapy had poor reporting quality. Encourage
eight items of the CONSORT Statement Adherence to CONSORT/presence of harms 17 (range: 14–21) for CONSORT; 7/22 = 77.3% for harm Adherence to CONSORT Statement A 25-item 2010 revised CONSORT Statement P000. of the studies: Some items were reported in more than P000. of the studies:			sample size calculation, which was assessed with		more use of CONSORT Statement
Adherence to CONSORT/presence of harms 17 (range: 14–21) for CONSORT; 7/22 = guidelines in RCTs 77.3% for harm 77.3% for harm A 25-item 2010 revised CONSORT Statement No combined data: only a few items were reported in less than 50% of the studies; some items were reported in more than 90%. Af the studies		;	eight items of the CONSORT Statement		
guidelines in RCTs 77.3% for harm A 25-item 2010 revised CONSORT Statement No combined data: only a few items were reported in less than 50% of the studies; some items were reported in more than 90% of the studies		Capili <sup>58</sup>	<b>ASORT</b>	I) for CONSORT; 7/22	Level of adherence is bad for quality of reporting, for
A 25-item 2010 revised CONSORT Statement No combined data: only a few items were reported in less than 50% of the studies; some items were reported in more than 90%, of the studies			guidelines in RCTs	77.3% for harm	RCTs on acupuncture, for pain reduction
		Cava da s <sup>59</sup>	A 25-item 2010 revised CONSORT Statement	No combined data: only a few items were	"RCTs in [pelvic organ prolapsed] are scarce. The quality
				reported in less than 50% of the studies;	of reporting is suboptimal in many aspects and has not
				some items were reported in more than	improved in recent years"
				90% of the studies	

175

Guideline	First author	Measure of quality	Results mean (SD)/% count	Authors' conclusion
	ء ٦	Percentage of articles that reported each applicable item of the CONSORT checklist	Sample size: only one (2.2%) of the papers mentioned sample size calculation. Randomization: 12 studies (26.1%) were deemed to have authentic randomization. Blinding: 36 papers (78.3%) provided no information about blinding of either participants or investigators. Reporting of baseline characteristics: 39 papers (84.8%) reported the details of the baseline characteristics of participants. Length of follow-up: 22 papers (47.8%). There was no information provided on the length of time for which participants were followed. Loss-to-follow-up: a total of 36 studies (78.3%) failed to report dropout rates. Statistical reporting: only one paper (2.2%) did not report what statistical methods they had used	Findings indicate that the reporting quality of RCTs needs improvement for RCTs on the treatment of cancer pain in People's Republic of China
	Chowers <sup>50</sup>	CONSOR1 guidelines for adverse events, adjusted to the design of the HAART trial	No combined score: harms were reported in only 24% of trials, 1/49 reported on adverse events collection method	Large variability and a lack of standard reporting of adverse events between trials; many trials did not adhere to CONSORT recommendations
	de Vries <sup>62</sup>	Adequate reporting of adverse drug reactions	Mean of 3, and 18% of articles scored 6 or higher	Insufficient reporting quality in adverse event reporting in RCTs of children
	Ethgen <sup>63</sup>	CLEAR NPT – a checklist to evaluate RCTs of nonpharmacological treatments	Most studies failed to report 8/12 quality indexes in the checklist. Reporting of generation of allocation sequence was adequate in 38.8% of studies, treatment allocation in 26.3%, intention-to-treat analysis in 70.0%	Inadequate reporting amongst trials involving stents. "The current reporting of results of RCTs testing stents needs to be improved to allow readers to appraise the risk of bias and the applicability of the results"
	Eyawo⁴	Revised CONSORT checklist to assess reporting of each items on the checklist in counts (percentage)	14/16 items ranged from 2%-47%; the other two items, sample size determination, and reporting of masking were reported in 72% and 75% of the articles	Deficiencies in the design, planning, and reporting of noninferiority and equivalence trials in ophthalmology literature
	Farrokhyar <sup>65</sup>	Modified CONSORT Statement and added factor relevant to surgical trials and CABG surgery	51.7 out of 105 (11.5)	The total reporting quality of trials in this review varied substantially between publications (35–96 out of a possible max score of 105). The results showed that there is a need for improvement in quality of reporting
	Froud <sup>48</sup>	Number and percentage of studies satisfying the revised 11-item consort checklist	Most items were reported in an adequate percentage of studies; 5/11 reported in 78%–100% of the studies	Their results suggest that cluster randomized trials in oral health are of reasonable quality with respect to the key criteria of accounting for clustering in the design and analysis

o i robe) Gagnier <sup>66</sup>	score of 37 points) statement indicators Mean CONSORT score based on 42 items and the percentage of items reported	89% and 83%, respectively 18.92 out of 42 (5.54), and 45% of items were reported across all trials	since the creation of CONSORT and STROBE "We found that reports of RCTs of herbal medicine interventions reported less than half of the necessary information in their published results"
Halpern <sup>67</sup>	Percentage of articles that reported each applicable item of the modified CONSORT checklist and count of articles complying with	In the 23 articles in Anesthesia and Analgesia, the median percentage of correct CONSORT items was 63%	Over all adjustments is now Poor – total number of items that are inadequately reported is high in the current RCT literature with obstetric anesthesia
Herdan <sup>69</sup>	22-item CONSORT checklist expressed	On average 87.4% of the CONSORT items were reported	The reporting quality has improved significantly in the period after dissemination of the CONSORT Statement; however reporting of adverse events needs attention
Kiehna <sup>46</sup>	Quality of reporting score using CONSORT (max score of 44) and Jadad score out of 5 points	26.4 out of 44 (range: 17–38)/67% of studies had no description or the prestudy sample size calculation, 63% did not describe whether subjects, treatment providers or assessors/analysts were blinded	The quality of reporting of RCTs in neurosurgical journals remains suboptimal
Kober <sup>21</sup>	CONSORT criteria based on a 14-item questionnaire	75% of studies reported only six of the 13 items; only 14% reported randomization process; only 13% provided details about concealment of allocation; only 13% provided a statement on study power; only 12% used intention-to-treat	Articles of Hodgkin's lymphoma published after 1996 do not conform to the CONSORT recommendations
Ladd <sup>25</sup>	Assessment of 36 of the items from the CONSORT Statement based on a score out of 36	24.43 out of 36 (3.27)	The overall level of adherence to CONSORT has improved since 1994, and continues to remain highest among studies that have been published within journals
L'2	Score out of 40 based on a 40-item modified checklist based on the CONSORT Statement	42% of the studies included explained how sample size was determined; 14% of studies described whether or not outcome assessors were blinded	The reporting quality of these trials is suboptimal and substantial improvement is required to meet the CONSORT guidelines. Almost 50% of the trials we reviewed did not satisfy more than half of the criteria in the modified CONSORT checklist, and only 23% of RCTs provided adequate details of Tai Chi intervention used in the trials
Marshman <sup>75</sup>	56 criteria based on the CONSORT Statement	27/56, with variation between journals (23.2 to 27.7)	Poor adherence to the CONSORT checklist in RCTs in dental health
Moberg-Mogren <sup>76</sup>	Average NMECI score (0–201 subitems scale)	104.2 (32.9)	Less than half of the articles met criteria of these subitems in selected RCTs relevant to occupational therapy

Table 2 (Continued)	/			
Guideline	First author	Measure of quality	Results mean (SD)/% count	Authors' conclusion
	Moher <sup>47</sup>	CONSORT checklist, frequency of unclear	12.7/32 of the CONSORT checklist included;	Overall, there was no difference in the PedCAM RCTs
		allocation concealment, and a five-point quality	81.3% unclear allocation concealment; 1.9/5	and conventional medicine quality, with both types
		assessment instrument (Jadad)	for the Jadad assessment scale	achieving 43% of their maximum possible outcome
	Montané <sup>77</sup>	Revised CONSORT checklist, 22 items	10.5 (2.7)	Quality was good in 23 (25%) of the articles and poor
				in 69 (75%) of the reports for RCTs on the efficacy of
	:			analgesic drugs in postoperative pain after TOS
	Montgomery <sup>30</sup>	Qualitative look	NA	Varying level of reporting quality factorial trials of
	Norton-Mabus <sup>78</sup>	NMNECI (212 subitems)	119.5 (25.48)	complex interventions in community settings Article consistency with CONSORT Statement was
				less than 60%. Occupational therapy RCT had higher
				consistency with the instrument, scoring higher than
	Parsons <sup>79</sup> (combined	Overall comuliance calculated as the weighted		articles in speech therapy Verv few noners fulfilling oll criterio: general lock of
	CONSORT and STROBE guideline)	mean of the compliance rates for the seven selected journals, using a previously made		statistical rigor
		questionnaire		
	Piggott <sup>80</sup>	Compared RCTs of three different time period	Quality of reporting variable; 30% of trials	Quality of reporting over time cohorts was variable, no
		cohorts, with the CONSORT (condensed, 13-	or less used true randomization, allocation	consistent improvement over time. Quality of reporting
		item) checklist	concealment, intention-to-treat analysis,	remains poor for RCTs in specialized palliative care
			and power calculations	literature
	Plint <sup>51</sup>	22-item checklist from the CONSORT Statement	Standardized mean difference between	Journal adoption of CONSORT is associated with
			CONSORT-adopting journals and	improved reporting of RCTs
	Rios <sup>81</sup>	Overall quality score, which is a 15 point overall reporting quality score made from CONSORT	10 (2.03)	Suboptimal reporting quality in an endocrine journal
		checklist		
	Strech <sup>83</sup>	A checklist based on the CONSORT Statement	There are 72 items on the checklist; 42%	While some trial-related information is well reported,
			were reported adequately and 25% were	a good part of the reporting quality of RCTs in bipolar
			reported inadequately	disorder falls well below the required and practically
				feasible level for many aspects essential for the adequate
				interpretation of methodological quality and clinical
				relevance. Authors should be further encouraged
				to follow the CONSORT criteria. No consistent
				trend could be shown for improvement in the quality
				of reporting over time, or for reporting essential
				methodological items differently. There is a consistent
				trend toward better reporting in journals that endorse
	Thabane <sup>84</sup>	Percentage of studies satisfying each of the	26.25 (4.51) and 60% adherence for	Overall, the quality of reporting is suboptimal in RCTs of
		44 CONSORT criteria	reporting criteria: 90% satisfied criteria for the introduction; 19% for the methods; 75%	weight loss intervention. Key reporting criteria that may impact the validity and generalizability of the results were
			the study protocol, 70% for the results	adequately reported

		· · · · · · · · · · · · · · · · · · ·
This will hopefully improve implementation and planning Adherence improved slightly after CONSORT for noninferiority trials Adherence was suboptimal for two-group parallel randomized controlled clinical trials of multiherb formulae Proper assessment of the credibility and generalizability of the results can be ensured by reporting quality Reporting on myeloid malignancies remains unsatisfactory and requires further improvement to properly assess the	valority or cuntear research Compliance with PRISMA reporting guidelines is low for systematic reviews on TCM published in Chinese journals Systematic reviews of empirical computerized provider order-entry research had moderate quality Compliance with the PRISMA statement was generally poor; none of the review completely adhered to all 27 checklist items for the published meta-analyses of diagnostic tests	"Reporting/scientific quality was considered less than fair- to-good. Stakeholders should strive for higher scientific quality of meta-analyses" The overall quality of reporting in the meta-analysis of RCTs in major depressive disorder was marginally acceptable Methodology and reporting quality are poor in both systematic reviews and meta-analysis of TCM published in journals in the People's Republic of China ( <i>Continued</i> )
half of the CONSORT-CRT criteria half of the CONSORT-CRT criteria No blinding in 34.0%, with only 45.7% reporting the method of determining the margin Of the 38 CONSORT items, only five items were described in more than 80% of the 153 included 17 CONSORT checklist items were reported in 7/18 studies, and 9/17 CONSORT checklist items were reported in all 18/18 studies 75% of the studies addressed 13 out of the 24 items of the CONSORT Statement	Title, introduction, limitations, and conclusions were reported well in 90% or more of the studies. Most other items varied from 30%–70% of the studies Mean = 63% (range 45%–81%) on a scale of 0%–100% Of the 236 meta-analyses included following selection: 1% reported the study protocol; 25% reported the searches used; 32% reported the results of a risk of bias assessment; and 35% reported the abstract as a structured summary	61% $\pm$ 19% (median 60%, range 39%–94%) for the QUOROM checklist. 58% $\pm$ 28% for OQAQ On average 50.2% of the CONSORT items were reported No combined score; methodological and reporting flaws in more than half of the review articles. Flaws were mainly in the literature search, characteristics of included and excluded studies, quality assessment of primary trials, and data merging
Extension of the CONSORT Statement for noninferiority and equivalence trial Number of studies describing each of the 38 modified consort items 17-item CONSORT checklist 24-item questionnaire based on the CONSORT checklist	Adherence to PRISMA checklist items (27 items) An integrated score consisting of the number of items completed over the total numbers of items on both the PRISMA and QUOROM criteria, resulting in cored ranking from 0% to 100% (excluding the items focused on in the abstract) Adherence to the 27-item PRISMA checklist	<ul> <li>18-item QUOROM checklist, ten-item checklist</li> <li>OQAQ used for scientific quality</li> <li>18-item QUOROM checklist, ten-item checklist</li> <li>OQAQ used for scientific quality</li> </ul>
Wangge <sup>52</sup> Zhong <sup>89</sup> Zintzaras <sup>53</sup>	Ma <sup>74</sup> Weir <sup>87</sup> (combined PRISMA and QUOROM guideline) Willis <sup>88</sup>	Bereza <sup>56</sup> Hemels <sup>68</sup> Junhua <sup>70</sup>
	PRISMA	QUOROM

Dovepress

FIRST AUTHOR	Measure of quality	Modules in courts	
Shea <sup>82</sup>	18-item QUOROM checklist, ten-item checklist	All systematic reviews were found to have	Reporting quality of Cochrane musculoskeletal systematic
	OQAQ used for scientific quality	good overall quality. OQAQ mean score	reviews was generally good, with room for improvement
		was 5.02 (95% CI 3.71–6.32)	
Vigna-Taglianti <sup>85</sup>	QUOROM-based checklist (score out of 50)	29.9/50	"Oncologists should be aware that they could be relying
			on poor underlying documents. Writing groups should be
			aware of methodological problems, and should consult the existing manuals for the preparation of guidelines."
Weir <sup>87</sup> (combined	An integrated score consisting of the number of	63% (range 45%–81%) on a scale of	Systematic reviews of empirical computerized provider
PRISMA and	items completed over the total numbers of items	%00/-%0	order-entry research were of moderate quality
QUOROM guideline)	on both the PRISMA and QUOROM criteria,		
	resulting in cored ranking from 0% to 100%		
	(excluding the items focused on in the abstract)		
Cook <sup>61</sup>	Quality of reporting, methodological quality, and	253 (90)	Reporting the quality of experimental research on
	the association between methodological quality		health profession education was found to be generally
	and effect size		suboptimal
Fung <sup>49</sup> (combined	STROBE (maximum score of 37 points) statement	STROBE mean and median: 70% and 71%,	Overall level of reporting is acceptable and has improved
CONSORT and	indicators	respectively	since the creation of CONSORT and STROBE
STROBE guideline)			
Parsons <sup>79</sup> (combined	Weighted mean of the compliance rates for the	58% (strobe)	Very few papers fulfilling all criteria, general lack of
CONSORT and	seven selected journals, using a previously made		statistical rigor
STROBE guideline)	questionnaire		
	Shea <sup>22</sup> Vigna-Taglianti <sup>85</sup> Weir <sup>87</sup> (combined PRISMA and QUOROM guideline) Cook <sup>61</sup> Fung <sup>49</sup> (combined CONSORT and STROBE guideline) Parsons <sup>79</sup> (combined CONSORT and STROBE guideline)	aglianti <sup>85</sup> (combined and OM guideline) SRT and E guideline) % (combined DRT and E guideline)	18-item QUOROM checklist, ten-item checklist         aglianti <sup>ns</sup> 0QAQ used for scientific quality         OQAQ used for scientific quality       0QAQ used for scientific quality         OQAQ used for scientific quality       0QAQ used for scientific quality         (combined       An integrated score consisting of the number of items completed over the total numbers of items         OM guideline)       on both the PRISMA and QUOROM criteria, resulting in cored ranking from 0% to 100% (excluding the items focused on in the abstract)         Quality of reporting, methodological quality, and the association between methodological quality and the association between methodological quality and the association between methodological quality and the associations         Regulateine)       Weighted mean of the compliance rates for the seven selected journals, using a previously made guideline)         Revenselected journals, using a previously made guideline)       Questionnaire

180

#### Table 3 Studies' conclusions

Type of guideline	Total number of studies	Number of studies concluding that "some improvements are needed, reporting
		inadequate, poor, medium, suboptimal, etc"
CONSORT	41 (two combined study with both CONSORT and STROBE)	<b>33 (80%)</b> <sup>21,43–46,54,55,57–60,62–67,69,71–73,75–81,83,84,86,89,90</sup>
PRISMA	3 (one combined study with both PRISMA and QUOROM)	3 (100%) <sup>74,87,88</sup>
QUOROM	6 (one combined study with both PRISMA and QUOROM)	3 (50%) <sup>56,70,87</sup>
STROBE	3 (two combined studies with both CONSORT and STROBE)	2 (67%) <sup>61,79</sup>
All guidelines	50 (distinct studies)	43 (86.0%) <sup>21,43-46,54-67,69-81,83,84,86-90</sup>

Abbreviations: CONSORT, Consolidated Standards of Reporting Trials; STROBE, Strengthening the Reporting of Observational Studies in Epidemiology; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; QUOROM, Quality of Reporting of Meta-analysis.

did not comment directly on an overall quality of reporting and concluded that adhering to reporting standards can ensure proper assessment of the results.

#### PRISMA, QUOROM, and STROBE

#### statements

Three studies examined adherence to the PRISMA guidelines, and all concluded that the adherence of the assessed systematic reviews was poor or moderate. Ma et al<sup>74</sup> and Willis et al<sup>88</sup> used the 27-item PRISMA checklist to assess the level of adherence. Ma et al<sup>74</sup> found that systematic reviews on traditional Chinese medicine published in Chinese journals had low adherence to the PRISMA checklist. Willis et al<sup>88</sup> also concluded that adherence to the PRISMA checklist was generally poor for published meta-analyses of diagnostic tests. Weir et al<sup>87</sup> used an integrated score consisting of both the PRISMA and QUOROM criteria and found that systematic reviews of empirical computerized provider order-entry research were only of moderate quality.

The assessment of studies' adherence to the QUOROM guideline was done with the 18-item QUOROM checklist coupled with a ten-item OQAQ checklist in three studies. Bereza et al<sup>56</sup> and Junhua et al<sup>70</sup> reported that there was a need to improve the quality of reporting of reviews, while Shea et al<sup>82</sup> concluded that the quality of Cochrane musculoskeletal systematic reviews was good. Hemels et al68 used only the QUOROM checklist and they concluded that the quality of meta-analyses in studies on major depressive disorder was marginally acceptable. Vigna-Taglianti et al<sup>85</sup> used the QUOROM checklist with a specific weighting system for each of the headings and the average score was 29.9/50. No conclusions concerning adherence were made, although the authors did recommend the use of manuals to prepare guidelines for the management of breast and colon cancers. Lastly, as described in the previous paragraph, Weir et al<sup>87</sup> used an integrated score containing both PRISMA and QUOROM criteria.

The studies by Fung et al<sup>49</sup> and Parsons et al<sup>79</sup> assessed the adherence of both RCTs and observational studies to their respective guidelines. Parsons et al<sup>79</sup> found there was a general lack of statistical rigor.

## Factors associated with adherence to reporting guidelines

Although we included systematic reviews assessing the adherence of research articles to four different guidelines, only systematic reviews related to the CONSORT Statement reported on the factors that were associated with adherence to the guideline (Table 4). The exception was Hemel et al,<sup>68</sup> who concluded that the overall quality of reporting of meta-analyses using the QUOROM guidelines did not significantly change over time, and that the year of publication was not associated with change in adherence. From the CONSORT-related studies, the following are the factors that were reported to be significantly associated with an increase in adherence to the CONSORT Statement or to the quality of reporting of RCTs, as well as the number of studies reporting these factors: publication in CONSORT-endorsing journals (3); declared funding source (1); high impact factor (3); industrial funding (1); multicenter studies (1); non-Chinese reports (compared to those published in mainland China) (1); number of authors (1); reporting of allocation concealment (1); reporting in a medical journal (1); reporting method of sequence generation (1); sample size (3); trial quality (1); type of intervention (pharmacologic intervention versus nonpharmacologic intervention); and year of publication (before and after CONSORT) (9). These factors are summarized in Table 4. Having a positive outcome in RCTs (compared to a neutral or negative outcome) was the only factor reported to be significantly associated with a decrease in adherence to the CONSORT Statement (Spearman correlation = -0.192; 95% CI, -0.351 to -0.011).<sup>55</sup> Other factors that reported but did not reach statistical significance for an association with adherence to the CONSORT Statement are also summarized in Table 4.

 Table 4 Factors associated with reporting quality of articles using the CONSORT guideline

173 120	I. Year of publication (1)
120	
	I. Publication in CONSORT-endorsing journals ( $\uparrow$ )
	2. Year of publication $(\uparrow)$
69	I. Number of authors $(\uparrow)^*$
	2. Multicenter studies $(\uparrow)^*$
	<ol> <li>Declared funding source (↑)*</li> </ol>
	4. Reporting in medical journals $(\uparrow)^*$
114	I. Trial quality $(\uparrow)^*$
	2. Trials with positive outcome $(\downarrow)^*$
	3. Year of publication $(\uparrow)^*$
10	I. Journal requiring the use of CONSORT $(\uparrow)$
49	I. Industry sponsored trials (industry sponsored versus nonindustry sponsored trial) ( $\uparrow$ )
	2. Year of publication $(\uparrow)^*$
107	I. Sponsoring $(\uparrow)$
132	I. Impact factor $(\uparrow)^*$
	2. Publication in CONSORT-endorsing journals $(\uparrow)^*$
50	I. Sample size $(\uparrow)^*$
	2. Year of publication (more recent publication year [up to 2005] [2001, $P = 0.822$ ;
	2002, P < 0.001; 2003, P = 0.204; 2004, P < 0.001; 2005, P < 0.001])
	3. Location of the study (UK, $P = 0.900$ ; Scandinavia, $P = 0.002$ ; Other, $P = 0.003$ )
	4. Source of funding $(\downarrow)$
	5. Type of primary outcome in the study-categorical ( $\downarrow$ )
37	I. Year of publication $(\uparrow)^*$
27	I. Publication in CONSORT-endorsing journals $(\uparrow)^*$
	I. Year of publication $(\uparrow)^*$
	I. Year of publication $(\uparrow)^*$
	I. Year of publication $(\uparrow)^*$
-	2. Impact factor $(\uparrow)^*$
	<ol> <li>Studies with placebo control group (<sup>1</sup>)</li> </ol>
76	I. Year of publication $(\uparrow)^*$
	1. Reporting method of sequence generation $(\uparrow)^*$
·	<ol> <li>Allocation concealment (1)*</li> </ol>
	3. Overall consort items (1)
89	I. Industrial funding $(\uparrow)^*$
07	2. Journal of publication (publication in JCEM) ( $\uparrow$ )*
	3. Sample size $(\uparrow)^*$
63	I. Sample size $(\uparrow)^*$
00	2. Year of publication $(\uparrow)^*$
	3. Type of intervention (pharmacologic intervention versus nonpharmacologic intervention) $(\uparrow)^*$
153	
155	1. Non-Chinese reports (compared to those published in mainland China) ( $\uparrow$ )* 2. Publication in CONSORT ordersing journals ( $\uparrow$ )*
261	2. Publication in CONSORT-endorsing journals $(\uparrow)^*$
201	I. Year of publication ( $\uparrow$ )* 2. Impact factor ( $\uparrow$ )*
	10 49 107 132 50

**Notes:** \*Statistically significant increase/decrease,  $P \le 0.05$ ; ( $\uparrow$ ) positively associated with adherence; ( $\downarrow$ ) negatively associated with adherence. **Abbreviations:** CONSORT, Consolidated Standards of Reporting Trials; JCEM, The Journal of Clinical Endocrinology and Metabolism.

# Quality of included studies, measured by the modified OQAQ/AMSTAR checklist

The global score of each of the studies is listed in Table 5. The mean global score of the 50 included studies was  $16.6 \pm 2.4$ . Twenty-one (42%) out of the 50 studies had a global score of 17 or more. The items with the lowest scores were question 5, "Was information on included and excluded

studies provided?" and question 6, "Were the characteristics of included studies provided?" with only 16% and 32% of the studies reporting each of these items correctly, respectively.

#### Discussion

We undertook a systematic scoping review of systematic reviews to investigate the adherence to reporting guidelines

 Table 5 Reporting quality of the 50 included systematic reviews, assessed by the modified AMSTAR/OQAQ (ten items, score out of 20)

First author	Global score
Al-Namankany <sup>54</sup>	15
Areia <sup>21</sup>	18
Augestad <sup>44</sup>	20
Balasubramanian <sup>45</sup>	16
Bath <sup>55</sup>	16
Bereza <sup>56</sup>	20
Bian <sup>43</sup>	15
Bousquet <sup>57</sup>	18
Capili <sup>58</sup>	15
Cavadas <sup>59</sup>	17
Lu <sup>73</sup>	18
Chowers <sup>60</sup>	12
Cook61	18
de Vries <sup>62</sup>	14
Ethgen <sup>63</sup>	13
Eyawo <sup>64</sup>	18
Farrokhyar <sup>65</sup>	19
Froud <sup>48</sup>	16
Fung <sup>49</sup>	17
Gagnier <sup>66</sup>	16
Halpern <sup>67</sup>	14
Hemels <sup>68</sup>	19
Herdan <sup>69</sup>	15
Junhua <sup>70</sup>	13
, Kiehna⁴	16
Kober <sup>71</sup>	17
Ladd <sup>25</sup>	19
Li <sup>72</sup>	18
Ma <sup>74</sup>	19
Marshman <sup>75</sup>	14
Moberg-Mogren <sup>76</sup>	16
Moher <sup>47</sup>	14
Montané <sup>77</sup>	15
Montgomery <sup>50</sup>	17
Norton-Mabus <sup>78</sup>	10
Parsons <sup>79</sup>	17
Piggott <sup>80</sup>	14
Plint <sup>51</sup>	18
Rios <sup>81</sup>	20
Shea <sup>82</sup>	19
Strech <sup>83</sup>	18
Thabane <sup>84</sup>	19
Vigna-Talianti <sup>85</sup>	15
Walleser <sup>86</sup>	19
Wangge <sup>52</sup>	12
Weir <sup>87</sup>	20
Willis <sup>88</sup>	20
Zhong <sup>89</sup>	17
Zintzaras <sup>53</sup>	18
Ziogas <sup>90</sup>	15
U -	

**Abbreviations:** AMSTAR, assessment of multiple systematic reviews; OQAQ, Overview Quality Assessment Questionnaire.

that included the CONSORT, PRISMA, OUOROM, TREND, MOOSE, and STROBE statements. Our systematic review included 50 studies that fulfilled our inclusion criteria, most of which originated from North American and European countries (43/50 studies). Despite the widespread acceptance of the CONSORT Statement and its subsequent extensions, the standards of reporting of clinical studies remained suboptimal. Our study showed that 86.0% of the systematic reviews included in this study concluded that there was a suboptimal quality of reporting across multidisciplinary clinical research topics using different study designs including RCTs and observational studies. The adherence of the assessed studies to reporting standards were not specific to any field of clinical research, but rather spanned across various disciplines including diagnostic procedures, interventions, cancer trials, and alternative medicine, implying the widespread lack of adherence to reporting guidelines in the medical literature. Despite the availability of guidelines and operational definitions of how to use these guidelines to improve reporting and transparency of clinical literature (including providing checklists, flow diagrams, and explicit methods of recruitment and allocation<sup>12</sup>), the uptake of these guidelines remained low. Several shortcomings of the reporting standards of clinical literature include inadequate reporting of the methods, selective reporting of the results, or misinterpretation of the results.91 Studies have shown that the use of these guidelines was associated with better reporting of studies of acupuncture trials,<sup>92</sup> and only minimal improvement in the adherence to reporting guidelines of studies that investigated diagnostic accuracy.93 It is possible that the lack of adherence may relate to the narrow focus of these guidelines on specific clinical areas or study designs, and therefore further guidelines need to be developed. Such new guidelines can be developed based on sets of tools and criteria, as proposed previously.94 The poor adherence to reporting guidelines seen in the clinical literature is also seen in other settings including the failure to follow the National Institute of Health guidelines for reporting sex and ethnicity in clinical trials.95 Efforts to address the gap between the standards set by the guidelines and the actual standards of the published literature are therefore needed.

The most striking observation from our study was the lack of consistency in methods of recording the adherence to the reporting guidelines, and therefore it was not possible to combine the results to provide a summary statistic. This highlights the need for a consensus statement on the reporting of methodological quality of studies addressing the adherence to CONSORT and other statements. Despite the suboptimal adherence to reporting guidelines in most of the studies reviewed, we observed that RCTs have a better adherence to reporting standards than non-RCTs. In addition, studies published in journals endorsing the CONSORT Statement have higher adherence to reporting standards. Not surprisingly, studies published after the introduction of CONSORT showed a better reporting quality and adherence to reporting guidelines. These findings are encouraging and provide a platform to disseminate knowledge generated by this study to multiple disciplines in health research to stress the need for improvement in adherence to reporting guidelines.

The strengths of our study are that we conducted a rigorous systematic review and included studies investigating the quality of reporting across various clinical areas of research, thus adding a scoping review methodology to a systematic review. We have also extracted relevant data and attempted to provide a summary statistic; however, the diversity of the findings did not allow for the computation of results.

Our study results are limited by the lack of reviews addressing adherence standards to other guidelines (MOOSE, TREND, QUOROM), the inability to combine the overall study findings, and the unavailability of tools designed to assess the quality of systematic reviews investigating methodological quality. Furthermore, the design, conduct, analysis, and reporting of the results of the reviews including definitions of outcomes (and predictor variables) varied substantially within and between the guidelines. This is mainly due to the lack of an established framework or standard for the conduct and reporting of reviews assessing the adherence to guidelines.

The study findings are nonetheless important for educators, authors, editors, sponsors, health consumers, and research ethics boards.

#### Summary and recommendations

Factors that are associated with reporting standards can be grouped into four categories:

- Study design: Better reporting standards were seen in studies with large sample sizes; RCT design; transparency in reporting randomization, adverse events, and secondary outcomes; and studies of drug interventions.
- Timing of publication: Studies that were published more recently were associated with better quality of reporting.
- Study sponsor: Studies with an industrial sponsor were also associated with a better quality of reporting.

• Journal: Journals with a high impact factor and those endorsing the CONSORT Statement and its extensions tended to publish studies with better adherence to reporting standards.

#### Recommendations for educators

Educators are at the forefront of teaching research methodology and applications in clinical settings, and therefore they play an important role in improving the reporting standards of clinical literature. Educators need to emphasize the importance of reporting standards and incorporate the guidelines in research training. They also need to provide ongoing training through workshops at professional meetings, and highlight the factors shown to improve the quality of reporting to foster improved reporting standards of the clinical literature.

#### Recommendations for authors

Authors should use the reporting standards appropriate to the study design as a guide to planning and reporting studies, and provide a flow diagram and checklist that will not only improve the reporting standard and adherence to guidelines, but will also help with transparency and reproducibility of the study. The use of the guidelines will also help to minimize reporting bias. For resources on using reporting standards, see the EQUATOR Network website.<sup>12</sup>

#### Recommendations for editors

Studies published in journals endorsing the CONSORT and its extensions were described as having better reporting quality and increased adherence to guidelines. Therefore, editors must endorse the reporting standards as part of their journal editorial policy.

Furthermore, inclusion of the respective guideline checklist must also be part of the editorial policy. Editors need to consider assessing the adherence to reporting guidelines as a requirement for peer review, and they should revise the peer review process to incorporate these assessments.

#### Recommendations for sponsors

Sponsors can ensure that the quality of the study methodology and transparency are meeting these standards by requesting adherence to the respective reporting guidelines appropriate for the study design.

## Recommendations for research ethics boards

Institutional Review Boards or Research Ethics Boards have a substantial responsibility to ensure ethical and sound methodological quality of clinical studies. Therefore, we recommend that Institutional Review Boards/Research Ethics Boards require that protocols be submitted for ethical approval to clearly state what reporting standards the study will be using based on the study design, and that reporting guidelines checklist are part of the application for ethics approval.

#### Recommendation for health consumers

In accordance with the general principles of evidence-based health care practice,<sup>96</sup> we encourage consumers or health care users to be actively involved in their health care by discussing their care options with their providers. Understanding information presented in published studies can be an important ingredient in these discussions. We suggest that health care users consider the evaluation of the quality of the information presented in the literature by looking for a guideline statement and a checklist to ensure the study reporting followed a certain standard that is appropriate for the particular study design.

Lastly, one element that all parties need to take into consideration is the importance of conducting large studies. Large studies have been shown to have a better quality of reporting.<sup>81,84,97</sup> Large studies are also less prone to problems of bias and have better precision.

#### Conclusion

Reporting guidelines help to improve the quality and transparency of clinical studies and allow for systematic reviews and meta-analyses to provide evidence worthy of changing practice, improving knowledge, and better management of health and disease. The current reporting standards and adherence to guidelines are poor and are in need of major improvement. Steps need to be taken by all involved in the conducting and reporting of clinical research in order to achieve better standards of reporting, thus minimizing bias and providing reproducible studies that can be combined to reach conclusive evidence.

## Acknowledgments

Special thanks to Neera Bhatnagar for the detailed discussion on literature search strategies. This study was funded in part by funds from the CANNeCTIN program.

ZS designed and wrote the first draft of the protocol and current manuscript; LM, DK, VBD, RD, SZ, VF, BD, and MB contributed to the protocol design and writing of the manuscript; LT conceived of the idea for the study and contributed to the design and writing of the manuscript. All authors read and approved the final draft.

#### Disclosure

The authors report no conflicts of interest in this work.

#### References

- US National Library of Medicine National Institutes of Health. PubMed. gov [homepage on the Internet]. Bethesda, MD: National Center for Biotechnology Information, US National Library of Medicine. Available from: http://www.ncbi.nlm.nih.gov/pubmed. Accessed February 1, 2013.
- US National Library of Medicine National Institutes of Health. PubMed. gov [webpage on the Internet]. Bethesda, MD: National Center for Biotechnology Information, US National Library of Medicine; 2013. Available from: http://www.ncbi.nlm.nih.gov/pubmed/?term=depressi on+systematic+review. Accessed February 1, 2013.
- 3. US National Library of Medicine National Institutes of Health. PubMed. gov [webpage on the Internet]. Bethesda, MD: National Center for Biotechnology Information, US National Library of Medicine; 2013. Available from: http://www.ncbi.nlm.nih.gov/pubmed/?term=cancer+ systematic+review. Accessed February 1, 2013.
- Greaves C, Sheppard K, Abraham C, et al. Systematic review of reviews of intervention components associated with increased effectiveness in dietary and physical activity interventions. *BMC Public Health*. 2011; 11(1):119.
- Tennant R, Goens C, Barlow J, Day C, Stewart-Brown S. A systematic review of reviews of interventions to promote mental health and prevent mental health problems in children and young people. *Journal of Public Mental Health.* 2007;6(1):25–32.
- Ernst E. A systematic review of systematic reviews of homeopathy. Br J Clin Pharmacol. 2002;54(6):577–582.
- Bloom BS. Effects of continuing medical education on improving physician clinical care and patient health: a review of systematic reviews. *Int J Technol Assess Health Care*. Summer 2005;21(3):380–385.
- Ernst E, Canter PH. A systematic review of systematic reviews of spinal manipulation. J R Soc Med. 2006;99(4):192–196.
- De Niet GJ, Tiemens BG, Kloos MW, Hutschemaekers GJ. Review of systematic reviews about the efficacy of non-pharmacological interventions to improve sleep quality in insomnia. *Int J Evid Based Healthc*. 2009;7(4):233–242.
- Brouwers MC, Garcia K, Makarski J, Daraz L. The landscape of knowledge translation interventions in cancer control: What do we know and where to next? A review of systematic reviews. *Implementation science: IS.* 2011;6:130.
- 11. Richards D. The EQUATOR network and website. *Evid Based Dent*. 2007;8(4):117.
- EQUATOR Network. Enhancing the QUAlity and Transparency Of health Research [homepage on the Internet]. Oxford, UK: EQUATOR Network; 2011. Available from: http://www.equator-network.org/home/. Accessed May 13, 2012.
- Simera I, Altman DG, Moher D, Schulz KF, Hoey J. Guidelines for reporting health research: the EQUATOR network's survey of guideline authors. *PLoS Med.* 2008;5(6):e139.
- CONSORT. CONSORT Transparent Reporting of Trials [homepage on the Internet]. Available from: http://www.consort-statement.org/. Accessed May 13, 2012.
- Schulz K, Altman D, Moher D, Group The CONSORT Group. CON-SORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. *BMC Medicine*. 2010;8(1):18.
- Shikata S, Nakayama T, Yamagishi H. Quality of surgical randomized controlled trials for acute cholecystitis: assessment based on CONSORT and additional check items. *J Hepatobiliary Pancreat Surg.* 2008;15(3):297–303.
- Süt N, Senocak M, Uysal O, Köksalan H. Assessing the quality of randomized controlled trials from two leading cancer journals using the CONSORT statement. *Hematol Oncol Stem Cell Ther.* 2008;1(1): 38–43.

- Uetani K, Nakayama T, Ikai H, Yonemoto N, Moher D. Quality of reports on randomized controlled trials conducted in Japan: evaluation of adherence to the CONSORT statement. *Intern Med.* 2009;48(5):307–313.
- Ziogas DC, Zintzaras E. Analysis of the quality of reporting of randomized controlled trials in acute and chronic myeloid leukemia, and myelodysplastic syndromes as governed by the CONSORT statement. *Ann Epidemiol.* 2009;19(7):494–500.
- Alvarez F, Meyer N, Gourraud PA, Paul C. CONSORT adoption and quality of reporting of randomized controlled trials: a systematic analysis in two dermatology journals. *Br J Dermatol.* 2009;161(5):1159–1165.
- Areia M, Soares M, Dinis-Ribeiro M. Quality reporting of endoscopic diagnostic studies in gastrointestinal journals: where do we stand on the use of the STARD and CONSORT statements? *Endoscopy*. 2010;42(2): 138–147.
- 22. Dasí F, Navarro-García MM, Jiménez-Heredia M, et al. Evaluation of the quality of publications on randomized clinical trials using the Consolidated Standards of Reporting Trials (CONSORT) statement guidelines in a Spanish tertiary hospital. *J Clin Pharmacol.* 2012;52(7): 1106–1114.
- 23. He J, Du L, Liu G, et al. Quality assessment of reporting of randomization, allocation concealment, and blinding in traditional Chinese medicine RCTs: a review of 3159 RCTs identified from 260 systematic reviews. *Trials*. 2011;12:122.
- Smith BA, Lee HJ, Lee JH, et al. Quality of reporting randomized controlled trials (RCTs) in the nursing literature: application of the consolidated standards of reporting trials (CONSORT). *Nurs Outlook*. 2008;56(1):31–37.
- Ladd BO, McCrady BS, Manuel JK, Campbell W. Improving the quality of reporting alcohol outcome studies: effects of the CONSORT statement. *Addict Behav*. 2010;35(7):660–666.
- Moher D, Hopewell S, Schulz KF, et al; for CONSORT. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. *Int J Surg.* 2012;10(1):28–55.
- Noah N. The STROBE initiative: STrengthening the Reporting of OBservational studies in Epidemiology (STROBE). *Epidemiol Infect*. 2008;136(7):865.
- Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. *Lancet.* 1999;354(9193):1896–1900.
- 29. Treasure E. The TREND statement. Evid Based Dent. 2004;5(4):88-91.
- Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. *JAMA*. 2000;283(15):2008–2012.
- Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *PLoS Med.* 2009;6(7):e1000100.
- Arksey H, O'Malley L. Scoping studies: towards a methodological framework. *Int J Soc Res Methodol*. 2005;8(1):19–32.
- Smith V, Devane D, Begley CM, Clarke M. Methodology in conducting a systematic review of systematic reviews of healthcare interventions. *BMC Med Res Methodol*. 2011;11(1):15.
- Brien SE, Lorenzetti DL, Lewis S, Kennedy J, Ghali WA. Overview of a formal scoping review on health system report cards. *Implement Sci.* 2010;5(2):2.
- Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ*. 2009;339:b2700.
- Montori VM, Wilczynski NL, Morgan D, Haynes RB. Optimal search strategies for retrieving systematic reviews from Medline: analytical survey. *BMJ*. 2005;330(7482):68.
- Wilczynski NL, Haynes RB. EMBASE search strategies achieved high sensitivity and specificity for retrieving methodologically sound systematic reviews. *J Clin Epidemiol.* 2007;60(1):29–33.

- Cohen J. A coefficient of agreement for nominal scales. *Educational* and Psychological Measurement. 1960;20(1):37.
- Shea BJ, Hamel C, Wells GA, et al. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. *J Clin Epidemiol*. 2009;62(10):1013–1020.
- Shea BJ, Bouter LM, Peterson J, et al. External validation of a measurement tool to assess systematic reviews (AMSTAR). *PLoS One*. 2007;2(12):e1350.
- 41. Shea BJ, Grimshaw JM, Wells GA, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. *BMC Med Res Methodol.* 2007;7:10.
- 42. Oxman AD, Guyatt GH, Singer J, et al. Agreement among reviewers of review articles. *J Clin Epidemiol*. 1991;44(1):91–98.
- 43. Bian ZX, Moher D, Dagenais S, et al. Improving the quality of randomized controlled trials in Chinese herbal medicine, part IV: applying a revised CONSORT checklist to measure reporting quality. Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine. 2006;4(3):233–242.
- 44. Augestad KM, Berntsen G, Lassen K, Bellika JG, Wootton R, Lindsetmo RO. Standards for reporting randomized controlled trials in medical informatics: a systematic review of CONSORT adherence in RCTs on clinical decision support. *J Am Med Inform Assoc*. 2012;19(1):13–21.
- 45. Balasubramanian SP, Wiener M, Alshameeri Z, Tiruvoipati R, Elbourne D, Reed MW. Standards of reporting of randomized controlled trials in general surgery: can we do better? *Annals of surgery*. 2006;244(5):663–667.
- Kiehna EN, Starke RM, Pouratian N, Dumont AS. Standards for reporting randomized controlled trials in neurosurgery. *J Neurosurg*. 2011;114(2):280–285.
- Moher D, Soeken K, Sampson M, Ben-Porat L, Berman B. Assessing the quality of reports of systematic reviews in pediatric complementary and alternative medicine. *BMC Pediatr.* 2002;2:3.
- Froud R, Eldridge S, Diaz Ordaz K, Marinho VC, Donner A. Quality of cluster randomized controlled trials in oral health: a systematic review of reports published between 2005 and 2009. *Community Dent Oral Epidemiol.* 2012;40 Suppl 1:3–14.
- Fung AE, Palanki R, Bakri SJ, Depperschmidt E, Gibson A. Applying the CONSORT and STROBE statements to evaluate the reporting quality of neovascular age-related macular degeneration studies. *Ophthalmology*. 2009;116(2):286–296.
- Montgomery AA, Astin MP, Peters TJ. Reporting of factorial trials of complex interventions in community settings: a systematic review. *Trials*. 2011;12:179.
- Plint AC, Moher D, Morrison A, et al. Does the CONSORT checklist improve the quality of reports of randomised controlled trials? A systematic review. *The Medical journal of Australia*. 2006;185(5): 263–267.
- Wangge G, Klungel OH, Roes KC, de Boer A, Hoes AW, Knol MJ. Room for improvement in conducting and reporting non-inferiority randomized controlled trials on drugs: a systematic review. *PLoS One*. 2010;5(10):e13550.
- Zintzaras E, Kitsios GD, Papathanasiou AA, et al. Randomized trials of dopamine agonists in restless legs syndrome: a systematic review, quality assessment, and meta-analysis. *Clin Ther*. 2010;32(2): 221–237.
- 54. Al-Namankany AA, Ashley P, Moles DR, Parekh S. Assessment of the quality of reporting of randomized clinical trials in paediatric dentistry journals. *Int J Paediatr Dent.* 2009;19(5): 318–324.
- Bath FJ, Owen VE, Bath PM. Quality of full and final publications reporting acute stroke trials: a systematic review. *Stroke*. 1998;29(10): 2203–2210.
- Bereza BG, Machado M, Einarson TR. Assessing the reporting and scientific quality of meta-analyses of randomized controlled trials of treatments for anxiety disorders. *Ann Pharmacother*. 2008;42(10): 1402–1409.

- 57. Bousquet PJ, Calderon MA, Demoly P, et al. The Consolidated Standards of Reporting Trials (CONSORT) Statement applied to allergen-specific immunotherapy with inhalant allergens: a Global Allergy and Asthma European Network (GA(2)LEN) article. *The Journal of Allergy and Clinical Immunology*. 2011;127(1):49–56, 56 e41–e11.
- Capili B, Anastasi JK, Geiger JN. Adverse event reporting in acupuncture clinical trials focusing on pain. *Clin J Pain*. 2010;26(1):43–48.
- Cavadas V, Branco F, Carvalho FL, Osorio L, Gomes MJ, Silva-Ramos M. The quality of reporting of randomized controlled trials in pelvic organ prolapse. *Int Urogynecol J*. 2011;22(9):1117–1125.
- Chowers MY, Gottesman BS, Leibovici L, Pielmeier U, Andreassen S, Paul M. Reporting of adverse events in randomized controlled trials of highly active antiretroviral therapy: systematic review. *Antimicrob Chemother*. 2009;64(2):239–250.
- Cook DA, Levinson AJ, Garside S. Method and reporting quality in health professions education research: a systematic review. *Med Educ*. 2011;45(3):227–238.
- de Vries TW, van Roon EN. Low quality of reporting adverse drug reactions in paediatric randomised controlled trials. *Arch Dis Child*. 2010;95(12):1023–1026.
- 63. Ethgen M, Boutron L, Steg PG, Roy C, Ravaud P. Quality of reporting internal and external validity data from randomized controlled trials evaluating stents for percutaneous coronary intervention. *BMC Med Res Methodol*. 2009;9:24.
- 64. Eyawo O, Lee CW, Rachlis B, Mills EJ. Reporting of noninferiority and equivalence randomized trials for major prostaglandins: a systematic survey of the ophthalmology literature. *Trials*. 2008;9:69.
- Farrokhyar F, Chu R, Whitlock R, Thabane L. A systematic review of the quality of publications reporting coronary artery bypass grafting trials. *Can J Surg.* 2007;50(4):266–277.
- Gagnier JJ, DeMelo J, Boon H, Rochon P, Bombardier C. Quality of reporting of randomized controlled trials of herbal medicine interventions. *Am J Med.* 2006;119(9):800 e801–e811.
- Halpern SH, Darani R, Douglas MJ, Wight W, Yee J. Compliance with the CONSORT checklist in obstetric anaesthesia randomised controlled trials. *Int J Obstet Anesth*. 2004;13(4):207–214.
- Hemels ME, Vicente C, Sadri H, Masson MJ, Einarson TR. Quality assessment of meta-analyses of RCTs of pharmacotherapy in major depressive disorder. *Curr Med Res Opin*. 2004;20(4):477–484.
- Herdan A, Roth R, Grass D, et al. Improvement of quality of reporting in randomised controlled trials to prevent hypotension after spinal anaesthesia for caesarean section. *Gynecol Surg.* 2011;8(2):121–127.
- Junhua Z, Hongcai S, Xiumei G, et al. Methodology and reporting quality of systematic review/meta-analysis of traditional Chinese medicine. *J Evid Based Complementary Altern Med.* 2007;13(8): 797–805.
- Kober T, Trelle S, Engert A. Reporting of randomized controlled trials in Hodgkin lymphoma in biomedical journals. *J Natl Cancer Inst.* 2006;98(9):620–625.
- Li JY, Zhang YF, Smith GS, et al. Quality of reporting of randomized clinical trials in tai chi interventions-a systematic review. *Evidence-Based Complementary and Alternative Medicine*. 2011;2011:383245.
- Lu L, Zeng J, Chen Y. Quality of reporting in randomized controlled trials conducted in China on the treatment of cancer pain. *Expert Rev Anticancer Ther.* 2011;11(6):871–877.
- 74. Ma B, Guo J, Qi G, et al. Epidemiology, quality and reporting characteristics of systematic reviews of traditional Chinese medicine interventions published in Chinese journals. *PLoS One*. 2011;6(5):e20185.
- Marshman Z, Farid F. The quality of reporting of randomised controlled trials in dental public health. *Community dental health*. 2010;27(4): 253–256.
- Moberg-Mogren E, Nelson DL. Evaluating the quality of reporting occupational therapy randomized controlled trials by expanding the CONSORT criteria. *Am J Occup Ther*. 2006;60(2):226–235.
- Montane E, Vallano A, Vidal X, Aguilera C, Laporte JR. Reporting randomised clinical trials of analgesics after traumatic or orthopaedic surgery is inadequate: a systematic review. *BMC Clin Pharmol.* 2010;10(2).

- Norton-Mabus JC, Nelson DL. Reporting of randomized controlled trials in occupational therapy and speech therapy: evaluation using an expansion of the CONSORT statement. *OTJR (Thorofare N J)*. 2008;28(2):64–71.
- Parsons NR, Hiskens R, Price CL, Achten J, Costa ML. A systematic survey of the quality of research reporting in general orthopaedic journals. *J Bone Joint Surg Br.* 2011;93(9):1154–1159.
- Piggott M, McGee H, Feuer D. Has CONSORT improved the reporting of randomized controlled trials in the palliative care literature? A systematic review. *Palliat Med.* 2004;18(1):32–38.
- Rios LP, Odueyungbo A, Moitri MO, Rahman MO, Thabane L. Quality of reporting of randomized controlled trials in general endocrinology literature. J Clin Endocrinol Metab. 2008;93(10):3810–3816.
- Shea B, Bouter LM, Grimshaw JM, et al. Scope for improvement in the quality of reporting of systematic reviews. From the Cochrane Musculoskeletal Group. *J Rheumatol.* 2006;33(1):9–15.
- 83. Strech D, Soltmann B, Weikert B, Bauer M, Pfennig A. Quality of reporting of randomized controlled trials of pharmacologic treatment of bipolar disorders: a systematic review. J Clin Psychiatry. 2011;72(9):1214–1221.
- Thabane L, Chu R, Cuddy K, Douketis J. What is the quality of reporting in weight loss intervention studies? A systematic review of randomized controlled trials. *Int J Obes (Lond)*. 2007;31(10):1554–1559.
- Vigna-Taglianti F, Vineis P, Liberati A, Faggiano F. Quality of systematic reviews used in guidelines for oncology practice. *Ann Oncol.* 2006;17(4):691–701.
- Walleser S, Hill SR, Bero LA. Characteristics and quality of reporting of cluster randomized trials in children: reporting needs improvement. *J Clin Epidemiol.* 2011;64(12):1331–1340.
- Weir CR, Staggers N, Laukert T. Reviewing the impact of computerized provider order entry on clinical outcomes: The quality of systematic reviews. *Int J Med Inform.* 2012;81(4):219–231.
- Willis BH, Quigley M. The assessment of the quality of reporting of meta-analyses in diagnostic research: a systematic review. *BMC Med Res Methodol.* 2011;11:163.
- Zhong YZ Wei, Jiang Hongli, Fan Tao, et al. Quality of reporting of two-group parallel randomized controlled clinical trials of multi-herb formulae: A survey of reports indexed in the Science Citation Index Expanded. *Eur J Integr Med.* 2011;3(4):E303–E310.
- Ziogas DCZ, E. Analysis of the quality of reporting of randomized controlled trials in acute and chronic myeloid leukemia, and myelodysplastic syndromes as governed by the CONSORT statement. *Ann Epidemiol.* 2009;19(7):494–500.
- Simera I, Moher D, Hirst A, Hoey J, Schulz KF, Altman DG. Transparent and accurate reporting increases reliability, utility, and impact of your research: reporting guidelines and the EQUATOR Network. *BMC Medicine*. 2010;8:24.
- Prady SL, Richmond SJ, Morton VM, Macpherson H. A systematic evaluation of the impact of STRICTA and CONSORT recommendations on quality of reporting for acupuncture trials. *PLoS One*. 2008;3(2):e1577.
- Smidt N, Rutjes AW, van der Windt DA, et al. The quality of diagnostic accuracy studies since the STARD statement: has it improved? *Neurology*. 2006;67(5):792–797.
- 94. Moher D, Schulz KF, Simera I, Altman DG. Guidance for developers of health research reporting guidelines. *PLoS medicine*. Feb 2010;7(2):e1000217.
- Geller S, Adams M, Carnes M. Adherence to federal guidelines for reporting of sex and race/ethnicity in clinical trials. *J Womens Health* (*Larchmt*). 2006;15(10):1123–1131.
- 96. Guyatt GH, Haynes RB, Jaeschke RZ, et al. Users' Guides to the Medical Literature: XXV. Evidence-based medicine: principles for applying the Users' Guides to patient care. Evidence-Based Medicine Working Group. JAMA 2000;284(10):1290–1296.
- Aleissa S, Parsons D, Grant J, Harder J, Howard J. Deep wound infection following pediatric scoliosis surgery: incidence and analysis of risk factors. *Can J Surg.* 2011;54(4):263–269.

#### Journal of Multidisciplinary Healthcare

#### Publish your work in this journal

The Journal of Multidisciplinary Healthcare is an international, peerreviewed open-access journal that aims to represent and publish research in healthcare areas delivered by practitioners of different disciplines. This includes studies and reviews conducted by multidisciplinary teams as well as research which evaluates the results or conduct of such teams or healthcare processes in general. The journal covers a wide range of areas and welcomes submission from practitioners at all levels, from all over the world. The manuscript management system is completely online and includes a very quick and fair peer-review system. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

 $\textbf{Submit your manuscript here:} \ \texttt{http://www.dovepress.com/journal-of-multidisciplinary-healthcare-journal}$ 

**Dove**press